{
    "nodes": [
        {
            "ix": "9-662_v1_0",
            "content": "SMARCB1/INI1-deficient tumors of adulthood",
            "ntype": "article-title",
            "meta": {
                "created_by": "F1000XMLParser"
            }
        },
        {
            "ix": "9-662_v1_1",
            "content": "Abstract",
            "ntype": "abstract",
            "meta": {
                "created_by": "F1000XMLParser"
            }
        },
        {
            "ix": "9-662_v1_2",
            "content": "The SMARCB1/INI1 gene was first discovered in the mid-1990\u2019s, and since then it has been revealed that loss of function mutations in this gene result in aggressive rhabdoid tumors. Recently, the term \u201crhabdoid tumor\u201d has become synonymous with decreased SMARCB1/INI1 expression. When genetic aberrations in the SMARCB1/INI1 gene occur, the result can cause reduced, complete loss, and mosaic expression. Although SMARCB1/INI1-deficient tumors are predominantly sarcomas, this is a diverse group of tumors with mixed phenotypes, which can often make the diagnosis challenging. Prognosis for these aggressive tumors is often poor. Moreover, refractory and relapsing progressive disease is common. As a result, accurate and timely diagnosis is imperative. Despite the SMARCB1/INI1 gene itself and its implications in tumorigenesis being discovered over two decades ago, there is a paucity of rhabdoid tumor cases reported in the literature that detail SMARCB1/INI1 expression. Much work remains if we hope to provide additional therapeutic strategies for patients with aggressive SMARCB1/INI1-deficient tumors.",
            "ntype": "p",
            "meta": {
                "created_by": "F1000XMLParser"
            }
        },
        {
            "ix": "9-662_v1_3",
            "content": "History of the SMARCB1/INI1 Gene",
            "ntype": "title",
            "meta": {
                "section": "1",
                "created_by": "F1000XMLParser"
            }
        },
        {
            "ix": "9-662_v1_4",
            "content": "SWI/SNF-related matrix-associated actin-dependent regulator of chromatin subfamily B member 1 (SMARCB1), also known as integrase interactor 1 (INI1), is a crucial component of a chromatin-remodeling protein complex. SMARCB1/INI1 was first identified in yeast in the late 1980\u2019s <REF-1> . By 1994, its human homologue was isolated in fibroblast cells <REF-2> , <REF-3> . Subsequent molecular investigations showed this nuclear protein complex enhances DNA transcription by interactions with HIV-1 integrase <REF-2> . Nuclear SMARCB1/INI1 exists ubiquitously in all normal cells, and acts as a tumor suppressor gene <REF-4> . It was revealed in the early 2000\u2019s by studies in mice that biallelic knockout of the SMARCB1/INI1 gene resulted in early lethality <REF-5> . Mice with heterozygous loss before birth, or who had later conditional single-allele knockout after birth, of SMARCB1/INI1 developed aggressive rhabdoid tumors <REF-6> \u2013 <REF-8> . Since its discovery, much work has revealed this chromatin-remodeling protein has crucial roles in multiple signaling pathways that function to suppress tumorigenesis and tumor growth <REF-9> . Although these pathways are highly complex, the development and use of targeted anti-cancer therapies has practically become ubiquitous for nearly all solid tumors. Thus, continued investigations are needed if we hope to provide additional therapeutic strategies for patients with aggressive SMARCB1/INI1-deficient tumors <REF-9> .",
            "ntype": "p",
            "meta": {
                "created_by": "F1000XMLParser"
            }
        },
        {
            "ix": "9-662_v1_5",
            "content": "Interestingly, the genetic signatures of SMARCB1/INI1-deficient tumors are far from monotonous. Three distinct patterns of abnormal SMARCB1/INI1 gene expression have been identified \u2013 reduced, complete loss, and mosaic <REF-9> .",
            "ntype": "p",
            "meta": {
                "created_by": "F1000XMLParser"
            }
        },
        {
            "ix": "9-662_v1_6",
            "content": "Epidemiology, clinical, prognosis",
            "ntype": "title",
            "meta": {
                "section": "2",
                "created_by": "F1000XMLParser"
            }
        },
        {
            "ix": "9-662_v1_7",
            "content": "Complete loss of SMARCB1/INI1 expression has been linked to a number of pediatric and adult sarcomas ( Table 1 ). Malignant rhabdoid tumor (MRT) and epithelioid sarcoma (ES) both result from biallelic deletions or mutations causing a complete loss of SMARCB1/INI1 expression <REF-41> . Commonly arising before the age of three years old, MRTs are considered one of the most aggressive childhood neoplasms associated with high mortality <REF-41> . MRTs have been reported in adults <REF-42> \u2013 <REF-49> . Based on MRT of adulthood being primarily reported anecdotally, estimated rates of incidence remain unclear. Data concerning the 5-year survival rate for MRT in adults is difficult to determine as well, as various percentages have been reported in literature <REF-13> , <REF-14> . However, estimated average survival following MRT diagnosis has been reported to be six months <REF-10> .",
            "ntype": "p",
            "meta": {
                "created_by": "F1000XMLParser"
            }
        },
        {
            "ix": "9-662_v1_8",
            "content": "Table 1.",
            "ntype": "label",
            "meta": {
                "id": "T1",
                "caption": "Epidemiologic, selected clinical, and prognostic data for SMARCB1/INI1-deficient tumors. STS, soft tissue sarcomas; MRT, malignant rhabdoid tumor; MPNST, malignant peripheral nerve sheath tumor; NF-1, neurofibromatosis type 1; NF-2; neurofibromatosis type 2, GI, gastrointestinal; NA, data not available.",
                "created_by": "F1000XMLParser"
            }
        },
        {
            "ix": "9-662_v1_9",
            "content": "<table-wrap xmlns:mml=\"http://www.w3.org/1998/Math/MathML\" xmlns:xlink=\"http://www.w3.org/1999/xlink\" id=\"T1\" position=\"anchor\"> <caption> <title>Epidemiologic, selected clinical, and prognostic data for SMARCB1/INI1-deficient tumors.</title> <p>STS, soft tissue sarcomas; MRT, malignant rhabdoid tumor; MPNST, malignant peripheral nerve sheath tumor; NF-1, neurofibromatosis type 1; NF-2; neurofibromatosis type 2, GI, gastrointestinal; NA, data not available.</p> </caption> <table content-type=\"article-table\" frame=\"hsides\"> <thead> <tr> <th align=\"center\" valign=\"top\"/> <th align=\"center\" valign=\"top\"/> <th align=\"center\" valign=\"top\">Epidemiology, Clinical</th> <th align=\"center\" valign=\"top\">Survival</th> </tr> </thead> <tbody> <tr> <td align=\"left\" valign=\"top\">Reduced <break/>expression</td> <td align=\"left\" valign=\"top\">Synovial sarcoma</td> <td align=\"left\" valign=\"top\">5 &#8211; 10% of all STS; median age of 40 years; <break/>males <sup> <xref ref-type=\"bibr\" rid=\"ref-10\">10</xref>, <xref ref-type=\"bibr\" rid=\"ref-11\">11</xref> </sup> </td> <td align=\"left\" valign=\"top\">5-year, 36&#8211;76% <sup> <xref ref-type=\"bibr\" rid=\"ref-11\">11</xref> </sup> </td> </tr> <tr> <td align=\"left\" rowspan=\"11\" valign=\"middle\">Complete loss</td> <td align=\"left\" valign=\"top\">Malignant rhabdoid <break/>tumor</td> <td align=\"left\" valign=\"top\">Typically &lt; 3 years of age <sup> <xref ref-type=\"bibr\" rid=\"ref-11\">11</xref> </sup>; typically presents in <break/>intraabdominally in adult males <sup> <xref ref-type=\"bibr\" rid=\"ref-10\">10</xref>, <xref ref-type=\"bibr\" rid=\"ref-12\">12</xref> </sup> </td> <td align=\"left\" valign=\"top\">MRT: 5-year, 15 &#8211; 20% <sup> <xref ref-type=\"bibr\" rid=\"ref-13\">13</xref> </sup>; <break/>extrarenal rhabdoid <break/>tumor: 5-year, 35% <sup> <xref ref-type=\"bibr\" rid=\"ref-14\">14</xref> </sup> </td> </tr> <tr> <td align=\"left\" valign=\"top\">Atypical teratoid/ <break/>rhabdoid tumor</td> <td align=\"left\" valign=\"top\">Typically &lt; 3 years of age; 10% of CNS tumors in <break/>infants <sup> <xref ref-type=\"bibr\" rid=\"ref-12\">12</xref> </sup> </td> <td align=\"left\" valign=\"top\">20 months <sup> <xref ref-type=\"bibr\" rid=\"ref-15\">15</xref>, <xref ref-type=\"bibr\" rid=\"ref-16\">16</xref> </sup> </td> </tr> <tr> <td align=\"left\" valign=\"top\">Epithelioid sarcoma</td> <td align=\"left\" valign=\"top\">&lt; 1% of all STS; median age of 27 years, males <sup> <xref ref-type=\"bibr\" rid=\"ref-17\">17</xref> </sup> </td> <td align=\"left\" valign=\"top\">5-year, 68% (all ages) <sup> <xref ref-type=\"bibr\" rid=\"ref-18\">18</xref> </sup> </td> </tr> <tr> <td align=\"left\" valign=\"top\">Renal medullary <break/>carcinoma</td> <td align=\"left\" valign=\"top\">Third most common kidney cancer among children <break/>and young adults; median age of 28 years; males <sup> <xref ref-type=\"bibr\" rid=\"ref-19\">19</xref>, <xref ref-type=\"bibr\" rid=\"ref-20\">20</xref> </sup> </td> <td align=\"left\" valign=\"top\">Overall survival less <break/>than 12 months <sup> <xref ref-type=\"bibr\" rid=\"ref-19\">19</xref> </sup> </td> </tr> <tr> <td align=\"left\" valign=\"top\">Epithelioid malignant <break/>peripheral nerve sheath <break/>tumor</td> <td align=\"left\" valign=\"top\">&lt; 1% of all STS; &lt; 5% of all MPNSTs; aggressive <break/>MPNST variant; unlike MPNST uncommonly <break/>associated with NF-1; median age &gt; 40 years <sup> <xref ref-type=\"bibr\" rid=\"ref-21\">21</xref>, <xref ref-type=\"bibr\" rid=\"ref-22\">22</xref> </sup> </td> <td align=\"left\" valign=\"top\">5-year, 34 &#8211; 43% <sup> <xref ref-type=\"bibr\" rid=\"ref-22\">22</xref> </sup> </td> </tr> <tr> <td align=\"left\" valign=\"top\">Myoepithelial carcinoma</td> <td align=\"left\" valign=\"top\">About 70% occur in parotid gland; median age of <break/>55 years <sup> <xref ref-type=\"bibr\" rid=\"ref-23\">23</xref> </sup> </td> <td align=\"left\" valign=\"top\">5-year, 71% <sup> <xref ref-type=\"bibr\" rid=\"ref-24\">24</xref> </sup> </td> </tr> <tr> <td align=\"left\" valign=\"top\">Extraskeletal myxoid <break/>chondrosarcoma</td> <td align=\"left\" valign=\"top\">&lt; 3% of all STS; median age of 50 years; males <sup> <xref ref-type=\"bibr\" rid=\"ref-25\">25</xref> </sup> </td> <td align=\"left\" valign=\"top\">5-year, 80 &#8211; 90% <sup> <xref ref-type=\"bibr\" rid=\"ref-25\">25</xref> </sup> </td> </tr> <tr> <td align=\"left\" valign=\"top\">Chordoma</td> <td align=\"left\" valign=\"top\">Median age of 50 &#8211; 60 years in adults, males; <break/>median age of 10 &#8211; 12 years in children, females <sup> <xref ref-type=\"bibr\" rid=\"ref-26\">26</xref>, <xref ref-type=\"bibr\" rid=\"ref-27\">27</xref> </sup> </td> <td align=\"left\" valign=\"top\">5-year, 70% <sup> <xref ref-type=\"bibr\" rid=\"ref-28\">28</xref> </sup> </td> </tr> <tr> <td align=\"left\" valign=\"top\">Pancreas <break/>undifferentiated <break/>rhabdoid carcinoma</td> <td align=\"left\" valign=\"top\">Heterogeneous group of neoplasms; poorly <break/>characterized <sup> <xref ref-type=\"bibr\" rid=\"ref-29\">29</xref> </sup> </td> <td align=\"left\" valign=\"top\">NA</td> </tr> <tr> <td align=\"left\" valign=\"top\">Sinonasal basaloid <break/>carcinoma</td> <td align=\"left\" valign=\"top\">&lt; 5% of all head/neck cancers; 0.5 cases per <break/>100,000 population per year; males <sup> <xref ref-type=\"bibr\" rid=\"ref-30\">30</xref> </sup> </td> <td align=\"left\" valign=\"top\">Median overall survival <break/>17 months <sup> <xref ref-type=\"bibr\" rid=\"ref-31\">31</xref> </sup> </td> </tr> <tr> <td align=\"left\" valign=\"top\">Rhabdoid carcinoma of <break/>the gastrointestinal tract</td> <td align=\"left\" valign=\"top\">About 0.1% of all gastric cancers; &lt; 50 cases <break/>reported in the upper and lower GI tract <sup> <xref ref-type=\"bibr\" rid=\"ref-32\">32</xref>, <xref ref-type=\"bibr\" rid=\"ref-33\">33</xref> </sup> </td> <td align=\"left\" valign=\"top\">Overall survival six <break/>months <sup> <xref ref-type=\"bibr\" rid=\"ref-33\">33</xref> </sup> </td> </tr> <tr> <td align=\"left\" rowspan=\"3\" valign=\"middle\">Mosaic <break/>expression</td> <td align=\"left\" valign=\"top\">Schwannomatosis</td> <td align=\"left\" valign=\"top\">Third major form of neurofibromatosis; distinct <break/>from NF-1 and NF-2; median age of 40 years; 20% <break/>familial <sup> <xref ref-type=\"bibr\" rid=\"ref-34\">34</xref> </sup> </td> <td align=\"left\" valign=\"top\">NA</td> </tr> <tr> <td align=\"left\" valign=\"top\">Gastrointestinal stromal <break/>tumor</td> <td align=\"left\" valign=\"top\">5% of all STS, 80% of all mesenchymal GI tract <break/>tumors; median age of 60 years <sup> <xref ref-type=\"bibr\" rid=\"ref-35\">35</xref>&#8211; <xref ref-type=\"bibr\" rid=\"ref-37\">37</xref> </sup> </td> <td align=\"left\" valign=\"top\">5-year, 83% <sup> <xref ref-type=\"bibr\" rid=\"ref-38\">38</xref> </sup> </td> </tr> <tr> <td align=\"left\" valign=\"top\">Ossifying fibromyxoid <break/>tumor</td> <td align=\"left\" valign=\"top\">Only 300 cases reported worldwide; median age of <break/>50 years; males <sup> <xref ref-type=\"bibr\" rid=\"ref-39\">39</xref>, <xref ref-type=\"bibr\" rid=\"ref-40\">40</xref> </sup> </td> <td align=\"left\" valign=\"top\">NA</td> </tr> </tbody> </table> </table-wrap>",
            "ntype": "table-wrap",
            "meta": {
                "id": "T1",
                "caption": "Epidemiologic, selected clinical, and prognostic data for SMARCB1/INI1-deficient tumors. STS, soft tissue sarcomas; MRT, malignant rhabdoid tumor; MPNST, malignant peripheral nerve sheath tumor; NF-1, neurofibromatosis type 1; NF-2; neurofibromatosis type 2, GI, gastrointestinal; NA, data not available.",
                "created_by": "F1000XMLParser"
            }
        },
        {
            "ix": "9-662_v1_10",
            "content": "ES is now categorized into two subgroups: distal and proximal. Conventional or distal-type ES tends to be histologically similar squamous cells. Also, distal-type ES immunohistochemical (IHC) profiles can be diverse. Proximal-type ES is thought to be the more aggressive variant, and has an affinity for the proximal limbs of young adults. Microscopically, sheets of large rhabdoid tumor cells are predominantly observed <REF-50> . Based on more recent clinicopathologic and IHC data, many tumors that were previously diagnosed as a MRT are now classified as proximal ES <REF-51> .",
            "ntype": "p",
            "meta": {
                "created_by": "F1000XMLParser"
            }
        },
        {
            "ix": "9-662_v1_11",
            "content": "In addition to ES, atypical teratoid/rhabdoid tumor, renal medullary carcinoma, and pediatric chordoma are rare sarcomas that result from the complete loss of SMARCB1/INI1 expression ( Table 1 ). They predominantly occur in pediatric or young adult patients. Collectively, these neoplasms typically develop in the head/neck, CNS, thorax, kidneys, other visceral organs, retroperitoneum, trunk, and extremities <REF-12> , <REF-17> , <REF-19> , <REF-26> , <REF-52> . Exceedingly rare SMARCB1/INI1-deficient tumors that occur more commonly in adults include synovial sarcomas, epithelioid malignant peripheral nerve sheath tumor, myoepithelial carcinoma, extraskeletal myxoid chondrosarcoma, chordoma, schwannomatosis, gastrointestinal stromal tumors (GIST), and ossifying fibromyxoid tumor ( Table 1 ). On light microscopy, these sarcomatous neoplasms exist on a morphological spectrum. Tissue specimens are often composed of epithelioid or rhabdoid cells <REF-53> . However, other morphologic patterns have been described <REF-50> . Thus, the diagnosis of SMARCB1/INI1-deficient tumors can be difficult based on their polyphenotypic variation <REF-4> . SMARCB1/INI1 immunostaining can be used to confirm the diagnosis of an epithelioid or rhabdoid sarcoma because loss of SMARCB1/INI1 expression is rarely observed in other tumor types <REF-54> , <REF-55> . Thus, in the absence of this genetic alteration, other malignant soft tissue tumors with epithelioid-like morphologies can be more confidently ruled out, such as melanoma, rhabdomyosarcoma, and undifferentiated carcinoma.",
            "ntype": "p",
            "meta": {
                "created_by": "F1000XMLParser"
            }
        },
        {
            "ix": "9-662_v1_12",
            "content": "Aside from SMARCB1/INI1-deficient tumors sharing an aberration in the same gene, the relationship between these malignancies remains unclear. Following diagnosis in any age or organ, nearly all SMARCB1/INI1-deficient malignancies characteristically follow an aggressive clinical pattern and prognosis if often poor ( Table 1 ). Survival rates are often reportedly low, but they may not be accurate given low rates of incidence, and considerations for newer treatments. Also, survival can be highly dependent on surgical intervention and completeness of tumor resection, especially for chordomas. GIST are the most common sarcomas of the gastrointestinal (GI) tract. They commonly develop in the sixth decade of life and have no gender predominance <REF-35> . Following the diagnosis of a GIST, survival rates are highly variable and depend on specific biologic characteristics of the tumor, the type of treatment, and the risk of post-treatment recurrence <REF-36> .",
            "ntype": "p",
            "meta": {
                "created_by": "F1000XMLParser"
            }
        },
        {
            "ix": "9-662_v1_13",
            "content": "Challenges in retrospective data collection for adult cases of SMARCB1/INI-deficient tumors",
            "ntype": "title",
            "meta": {
                "section": "3",
                "created_by": "F1000XMLParser"
            }
        },
        {
            "ix": "9-662_v1_14",
            "content": "Recently, the term \u201crhabdoid tumor\u201d has become synonymous with tumors that harbor loss of function mutations in the SMARCB1/INI1 gene <REF-56> . We reviewed the literature and found a paucity of cases reporting SMARCB1/INI1 genetic aberrations in adult patients with sarcomas. A total of 450 cases of rare sarcomas were found to be described in single case reports, case series, or systematic reviews published between the years 2000 \u2013 2020 ( Table 2 ) <REF-57> \u2013 <REF-92> . This number is likely far lower than the actual accounts of reported sarcoma cases in the literature. However, reports were excluded if it was apparent the case did not meet our inclusion criteria based on the publicly-available title or abstract information. Despite the SMARCB1/INI1 gene being discovered in the mid-1990\u2019s, the majority of previous reports were excluded for not mentioning the tumor\u2019s SMARCB1/INI1-deficiency status. Also, tumor occurrence in the pediatric patient population accounted for multiple exclusions.",
            "ntype": "p",
            "meta": {
                "created_by": "F1000XMLParser"
            }
        },
        {
            "ix": "9-662_v1_15",
            "content": "Table 2.",
            "ntype": "label",
            "meta": {
                "id": "T2",
                "caption": "Excluded rare sarcomas in adults reported in single case reports, case series, or systematic reviews, 2000\u20132020. Exclusion criteria was as follows: 1.) individual patient age could not be confirmed; 2.) pediatric study population (less than 18 years of age); 3.) absence of documentation noting the loss of SMARCB1/INI1 expression by immunohistochemistry or genetic studies; 4.) intact SMARCB1/INI1 expression by immunochemistry or genetic studies; and 5.) non-sarcomatous histologic tumor type. PMID, PubMed Central \u00a9 unique article identifier; GU, genitourinary; PNS, peripheral nervous system; GI, gastrointestinal.",
                "created_by": "F1000XMLParser"
            }
        },
        {
            "ix": "9-662_v1_16",
            "content": "<table-wrap xmlns:mml=\"http://www.w3.org/1998/Math/MathML\" xmlns:xlink=\"http://www.w3.org/1999/xlink\" id=\"T2\" position=\"anchor\"> <caption> <title>Excluded rare sarcomas in adults reported in single case reports, case series, or systematic reviews, 2000&#8211;2020.</title> <p>Exclusion criteria was as follows: 1.) individual patient age could not be confirmed; 2.) pediatric study population (less than 18 years of age); 3.) absence of documentation noting the loss of <italic>SMARCB1/INI1</italic> expression by immunohistochemistry or genetic studies; 4.) intact <italic>SMARCB1/INI1</italic> expression by immunochemistry or genetic studies; and 5.) non-sarcomatous histologic tumor type. PMID, PubMed Central &#169; unique article identifier; GU, genitourinary; PNS, peripheral nervous system; GI, gastrointestinal.</p> </caption> <table content-type=\"article-table\" frame=\"hsides\"> <thead> <tr> <th align=\"center\" valign=\"middle\">Article</th> <th align=\"center\" valign=\"middle\">PMID</th> <th align=\"center\" valign=\"top\">Cases, <break/>no.</th> <th align=\"center\" valign=\"top\">Tumor <break/>site</th> <th align=\"center\" valign=\"top\">Exclusion <break/>reason</th> <th align=\"center\" valign=\"middle\">Article</th> <th align=\"center\" valign=\"middle\">PMID</th> <th align=\"center\" valign=\"top\">Cases, <break/>no.</th> <th align=\"center\" valign=\"top\">Tumor <break/>site</th> <th align=\"center\" valign=\"top\">Exclusion <break/>reason</th> </tr> </thead> <tbody> <tr> <td align=\"left\" valign=\"top\">Zhang <italic>et al.</italic>, 2019 <sup> <xref ref-type=\"bibr\" rid=\"ref-57\">57</xref> </sup> </td> <td align=\"center\" valign=\"top\">31933781</td> <td align=\"center\" valign=\"top\">1</td> <td align=\"center\" valign=\"top\">scalp</td> <td align=\"center\" valign=\"top\">3</td> <td align=\"left\" valign=\"top\">Weisskopf <italic>et al.</italic>, <break/>2006 <sup> <xref ref-type=\"bibr\" rid=\"ref-75\">75</xref> </sup> </td> <td align=\"center\" valign=\"top\">16474944</td> <td align=\"center\" valign=\"top\">1</td> <td align=\"center\" valign=\"top\">spine</td> <td align=\"center\" valign=\"top\">2,3</td> </tr> <tr> <td align=\"left\" valign=\"top\">Kubota <italic>et al.</italic>, 2019 <sup> <xref ref-type=\"bibr\" rid=\"ref-58\">58</xref> </sup> </td> <td align=\"center\" valign=\"top\">31034722</td> <td align=\"center\" valign=\"top\">1</td> <td align=\"center\" valign=\"top\">GU</td> <td align=\"center\" valign=\"top\">2</td> <td align=\"left\" valign=\"top\">Onol <italic>et al.</italic>, 2006 <sup> <xref ref-type=\"bibr\" rid=\"ref-76\">76</xref> </sup> </td> <td align=\"center\" valign=\"top\">16343734</td> <td align=\"center\" valign=\"top\">1</td> <td align=\"center\" valign=\"top\">GU</td> <td align=\"center\" valign=\"top\">3</td> </tr> <tr> <td align=\"left\" valign=\"top\">Kolin <italic>et al.</italic>, 2018 <sup> <xref ref-type=\"bibr\" rid=\"ref-59\">59</xref> </sup> </td> <td align=\"center\" valign=\"top\">29700418</td> <td align=\"center\" valign=\"top\">5</td> <td align=\"center\" valign=\"top\">GU</td> <td align=\"center\" valign=\"top\">4</td> <td align=\"left\" valign=\"top\">Zevallos-G. <italic>et al.</italic>, <break/>2005 <sup> <xref ref-type=\"bibr\" rid=\"ref-77\">77</xref> </sup> </td> <td align=\"center\" valign=\"top\">16082246</td> <td align=\"center\" valign=\"top\">2</td> <td align=\"center\" valign=\"top\">perineum </td> <td align=\"center\" valign=\"top\">3</td> </tr> <tr> <td align=\"left\" valign=\"top\">Kim <italic>et al.</italic>, 2018 <sup> <xref ref-type=\"bibr\" rid=\"ref-60\">60</xref> </sup> </td> <td align=\"center\" valign=\"top\">30235775</td> <td align=\"center\" valign=\"top\">1</td> <td align=\"center\" valign=\"top\">brain</td> <td align=\"center\" valign=\"top\">3</td> <td align=\"left\" valign=\"top\">Masunaga <italic>et al.</italic>, <break/>2004 <sup> <xref ref-type=\"bibr\" rid=\"ref-78\">78</xref> </sup> </td> <td align=\"center\" valign=\"top\">15260853</td> <td align=\"center\" valign=\"top\">1</td> <td align=\"center\" valign=\"top\">lung</td> <td align=\"center\" valign=\"top\">3</td> </tr> <tr> <td align=\"left\" valign=\"top\">Strehl <italic>et al.</italic>, 2015 <sup> <xref ref-type=\"bibr\" rid=\"ref-61\">61</xref> </sup> </td> <td align=\"center\" valign=\"top\">25920939</td> <td align=\"center\" valign=\"top\">25</td> <td align=\"center\" valign=\"top\">GU</td> <td align=\"center\" valign=\"top\">3</td> <td align=\"left\" valign=\"top\">Chang <italic>et al.</italic>, 2004 <sup> <xref ref-type=\"bibr\" rid=\"ref-79\">79</xref> </sup> </td> <td align=\"center\" valign=\"top\">14713833</td> <td align=\"center\" valign=\"top\">1</td> <td align=\"center\" valign=\"top\">GI</td> <td align=\"center\" valign=\"top\">2</td> </tr> <tr> <td align=\"left\" valign=\"top\">Santos <italic>et al.</italic>, 2013 <sup> <xref ref-type=\"bibr\" rid=\"ref-62\">62</xref> </sup> </td> <td align=\"center\" valign=\"top\">23793215</td> <td align=\"center\" valign=\"top\">1</td> <td align=\"center\" valign=\"top\">pelvis</td> <td align=\"center\" valign=\"top\">3</td> <td align=\"left\" valign=\"top\">Altundag <italic>et al.</italic>, 2004 <sup> <xref ref-type=\"bibr\" rid=\"ref-80\">80</xref> </sup> </td> <td align=\"center\" valign=\"top\">15579921</td> <td align=\"center\" valign=\"top\">1</td> <td align=\"center\" valign=\"top\">GU</td> <td align=\"center\" valign=\"top\">3</td> </tr> <tr> <td align=\"left\" valign=\"top\">Patrizi <italic>et al.</italic>, 2013 <sup> <xref ref-type=\"bibr\" rid=\"ref-63\">63</xref> </sup> </td> <td align=\"center\" valign=\"top\">23886403</td> <td align=\"center\" valign=\"top\">1</td> <td align=\"center\" valign=\"top\">GU</td> <td align=\"center\" valign=\"top\">3</td> <td align=\"left\" valign=\"top\">Lee <italic>et al.</italic>, 2004 <sup> <xref ref-type=\"bibr\" rid=\"ref-81\">81</xref> </sup> </td> <td align=\"center\" valign=\"top\">14675288</td> <td align=\"center\" valign=\"top\">1</td> <td align=\"center\" valign=\"top\">pelvis</td> <td align=\"center\" valign=\"top\">3</td> </tr> <tr> <td align=\"left\" valign=\"top\">Zhao <italic>et al.</italic>, 2013 <sup> <xref ref-type=\"bibr\" rid=\"ref-49\">49</xref> </sup> </td> <td align=\"center\" valign=\"top\">23761028</td> <td align=\"center\" valign=\"top\">1</td> <td align=\"center\" valign=\"top\">renal</td> <td align=\"center\" valign=\"top\">3</td> <td align=\"left\" valign=\"top\">Peng <italic>et al.</italic>, 2003 <sup> <xref ref-type=\"bibr\" rid=\"ref-44\">44</xref> </sup> </td> <td align=\"center\" valign=\"top\">12946214</td> <td align=\"center\" valign=\"top\">1</td> <td align=\"center\" valign=\"top\">renal</td> <td align=\"center\" valign=\"top\">3</td> </tr> <tr> <td align=\"left\" valign=\"top\">Tocco <italic>et al.</italic>, 2012 <sup> <xref ref-type=\"bibr\" rid=\"ref-64\">64</xref> </sup> </td> <td align=\"center\" valign=\"top\">23359842</td> <td align=\"center\" valign=\"top\">1</td> <td align=\"center\" valign=\"top\">scalp</td> <td align=\"center\" valign=\"top\">3</td> <td align=\"left\" valign=\"top\">Hanna <italic>et al.</italic>, 2002 <sup> <xref ref-type=\"bibr\" rid=\"ref-82\">82</xref> </sup> </td> <td align=\"center\" valign=\"top\">12107573</td> <td align=\"center\" valign=\"top\">8</td> <td align=\"center\" valign=\"top\">multiple </td> <td align=\"center\" valign=\"top\">3</td> </tr> <tr> <td align=\"left\" valign=\"top\">Rizzo <italic>et al.</italic>, 2012 <sup> <xref ref-type=\"bibr\" rid=\"ref-65\">65</xref> </sup> </td> <td align=\"center\" valign=\"top\">22614000</td> <td align=\"center\" valign=\"top\">12</td> <td align=\"center\" valign=\"top\">PNS</td> <td align=\"center\" valign=\"top\">2</td> <td align=\"left\" valign=\"top\">Etienne-M. <italic>et al.</italic>, <break/>2002 <sup> <xref ref-type=\"bibr\" rid=\"ref-83\">83</xref> </sup> </td> <td align=\"center\" valign=\"top\">12445750</td> <td align=\"center\" valign=\"top\">12</td> <td align=\"center\" valign=\"top\">multiple </td> <td align=\"center\" valign=\"top\">3,5</td> </tr> <tr> <td align=\"left\" valign=\"top\">Kuge <italic>et al.</italic>, 2012 <sup> <xref ref-type=\"bibr\" rid=\"ref-66\">66</xref> </sup> </td> <td align=\"center\" valign=\"top\">22218708</td> <td align=\"center\" valign=\"top\">1</td> <td align=\"center\" valign=\"top\">brain</td> <td align=\"center\" valign=\"top\">2</td> <td align=\"left\" valign=\"top\">Moore <italic>et al.</italic>, 2002 <sup> <xref ref-type=\"bibr\" rid=\"ref-84\">84</xref> </sup> </td> <td align=\"center\" valign=\"top\">11925150</td> <td align=\"center\" valign=\"top\">1</td> <td align=\"center\" valign=\"top\">GU</td> <td align=\"center\" valign=\"top\">3</td> </tr> <tr> <td align=\"left\" valign=\"top\">Hagstr&#246;m <italic>et al.</italic>, <break/>2011 <sup> <xref ref-type=\"bibr\" rid=\"ref-67\">67</xref> </sup> </td> <td align=\"center\" valign=\"top\">21420628</td> <td align=\"center\" valign=\"top\">1</td> <td align=\"center\" valign=\"top\">oral </td> <td align=\"center\" valign=\"top\">3</td> <td align=\"left\" valign=\"top\">Haidopoulos <italic>et al.</italic>, <break/>2002 <sup> <xref ref-type=\"bibr\" rid=\"ref-85\"/> </sup> </td> <td align=\"center\" valign=\"top\">12440823</td> <td align=\"center\" valign=\"top\">1</td> <td align=\"center\" valign=\"top\">GU</td> <td align=\"center\" valign=\"top\">3</td> </tr> <tr> <td align=\"left\" valign=\"top\">Narendra <italic>et al.</italic>, <break/>2010 <sup> <xref ref-type=\"bibr\" rid=\"ref-68\">68</xref> </sup> </td> <td align=\"center\" valign=\"top\">20479553</td> <td align=\"center\" valign=\"top\">1</td> <td align=\"center\" valign=\"top\">GU</td> <td align=\"center\" valign=\"top\">3</td> <td align=\"left\" valign=\"top\">Tzilinis <italic>et al.</italic>, 2002 <sup> <xref ref-type=\"bibr\" rid=\"ref-86\">86</xref> </sup> </td> <td align=\"center\" valign=\"top\">16093195</td> <td align=\"center\" valign=\"top\">1</td> <td align=\"center\" valign=\"top\">GU</td> <td align=\"center\" valign=\"top\">3</td> </tr> <tr> <td align=\"left\" valign=\"top\">Tholpady <italic>et al.</italic>, <break/>2010 <sup> <xref ref-type=\"bibr\" rid=\"ref-69\">69</xref> </sup> </td> <td align=\"center\" valign=\"top\">20881848</td> <td align=\"center\" valign=\"top\">1</td> <td align=\"center\" valign=\"top\">GU</td> <td align=\"center\" valign=\"top\">2</td> <td align=\"left\" valign=\"top\">Amrikachi <italic>et al.</italic>, <break/>2002 <sup> <xref ref-type=\"bibr\" rid=\"ref-87\">87</xref> </sup> </td> <td align=\"center\" valign=\"top\">12478486</td> <td align=\"center\" valign=\"top\">4</td> <td align=\"center\" valign=\"top\">GI</td> <td align=\"center\" valign=\"top\">3</td> </tr> <tr> <td align=\"left\" valign=\"top\">Chbani <italic>et al.</italic>, 2009 <sup> <xref ref-type=\"bibr\" rid=\"ref-55\">55</xref> </sup> </td> <td align=\"center\" valign=\"top\">19141382</td> <td align=\"center\" valign=\"top\">106</td> <td align=\"center\" valign=\"top\">multiple </td> <td align=\"center\" valign=\"top\">1</td> <td align=\"left\" valign=\"top\">Hasegawa <italic>et al.</italic>, <break/>2001 <sup> <xref ref-type=\"bibr\" rid=\"ref-88\">88</xref> </sup> </td> <td align=\"center\" valign=\"top\">11454997</td> <td align=\"center\" valign=\"top\">20</td> <td align=\"center\" valign=\"top\">multiple </td> <td align=\"center\" valign=\"top\">3</td> </tr> <tr> <td align=\"left\" valign=\"top\">Hornick <italic>et al.</italic>, <break/>2009 <sup> <xref ref-type=\"bibr\" rid=\"ref-70\">70</xref> </sup> </td> <td align=\"center\" valign=\"top\">19033866</td> <td align=\"center\" valign=\"top\">127</td> <td align=\"center\" valign=\"top\">multiple </td> <td align=\"center\" valign=\"top\">1</td> <td align=\"left\" valign=\"top\">Kasamatsu <italic>et al.</italic>, <break/>2001 <sup> <xref ref-type=\"bibr\" rid=\"ref-89\">89</xref> </sup> </td> <td align=\"center\" valign=\"top\">11520372</td> <td align=\"center\" valign=\"top\">1</td> <td align=\"center\" valign=\"top\">GU</td> <td align=\"center\" valign=\"top\">3</td> </tr> <tr> <td align=\"left\" valign=\"top\">Kim <italic>et al.</italic>, 2008 <sup> <xref ref-type=\"bibr\" rid=\"ref-71\">71</xref> </sup> </td> <td align=\"center\" valign=\"top\">19471567</td> <td align=\"center\" valign=\"top\">1</td> <td align=\"center\" valign=\"top\">GU</td> <td align=\"center\" valign=\"top\">3</td> <td align=\"left\" valign=\"top\">Knapik <italic>et al.</italic>, 2001 <sup> <xref ref-type=\"bibr\" rid=\"ref-90\">90</xref> </sup> </td> <td align=\"center\" valign=\"top\">11521235</td> <td align=\"center\" valign=\"top\">1</td> <td align=\"center\" valign=\"top\">GU</td> <td align=\"center\" valign=\"top\">4</td> </tr> <tr> <td align=\"left\" valign=\"top\">Rekhi <italic>et al.</italic>, 2008 <sup> <xref ref-type=\"bibr\" rid=\"ref-72\">72</xref> </sup> </td> <td align=\"center\" valign=\"top\">18607629</td> <td align=\"center\" valign=\"top\">40</td> <td align=\"center\" valign=\"top\">multiple </td> <td align=\"center\" valign=\"top\">3</td> <td align=\"left\" valign=\"top\">Biegal <italic>et al.</italic>, 2000 <sup> <xref ref-type=\"bibr\" rid=\"ref-91\">91</xref> </sup> </td> <td align=\"center\" valign=\"top\">10738300</td> <td align=\"center\" valign=\"top\">1</td> <td align=\"center\" valign=\"top\">brain</td> <td align=\"center\" valign=\"top\">2</td> </tr> <tr> <td align=\"left\" valign=\"top\">Argenta <italic>et al.</italic>, <break/>2007 <sup> <xref ref-type=\"bibr\" rid=\"ref-73\">73</xref> </sup> </td> <td align=\"center\" valign=\"top\">17692365</td> <td align=\"center\" valign=\"top\">1</td> <td align=\"center\" valign=\"top\">GU</td> <td align=\"center\" valign=\"top\">3</td> <td align=\"left\" valign=\"top\">Spillane <italic>et al.</italic>, 2000 <sup> <xref ref-type=\"bibr\" rid=\"ref-92\">92</xref> </sup> </td> <td align=\"center\" valign=\"top\">10791853</td> <td align=\"center\" valign=\"top\">37</td> <td align=\"center\" valign=\"top\">multiple </td> <td align=\"center\" valign=\"top\">3</td> </tr> <tr> <td align=\"left\" valign=\"top\">Bourdeaut <break/> <italic>et al.</italic>, 2007 <sup> <xref ref-type=\"bibr\" rid=\"ref-74\">74</xref> </sup> </td> <td align=\"center\" valign=\"top\">17152049</td> <td align=\"center\" valign=\"top\">26</td> <td align=\"left\" valign=\"top\">multiple</td> <td align=\"center\" valign=\"top\">2</td> <td align=\"center\" valign=\"top\"/> <td align=\"center\" valign=\"top\"/> <td align=\"center\" valign=\"top\"/> <td align=\"center\" valign=\"top\"/> <td align=\"center\" valign=\"top\"/> </tr> </tbody> </table> </table-wrap>",
            "ntype": "table-wrap",
            "meta": {
                "id": "T2",
                "caption": "Excluded rare sarcomas in adults reported in single case reports, case series, or systematic reviews, 2000\u20132020. Exclusion criteria was as follows: 1.) individual patient age could not be confirmed; 2.) pediatric study population (less than 18 years of age); 3.) absence of documentation noting the loss of SMARCB1/INI1 expression by immunohistochemistry or genetic studies; 4.) intact SMARCB1/INI1 expression by immunochemistry or genetic studies; and 5.) non-sarcomatous histologic tumor type. PMID, PubMed Central \u00a9 unique article identifier; GU, genitourinary; PNS, peripheral nervous system; GI, gastrointestinal.",
                "created_by": "F1000XMLParser"
            }
        },
        {
            "ix": "9-662_v1_17",
            "content": "We located 25 cases of adult SMARCB1/INI1-deficient sarcomas that were described in 18 reports ( Table 3 ) <REF-42> , <REF-50> , <REF-93> \u2013 <REF-108> . Median age at the time of diagnosis was 36 years old. A male predominance was mildly observed (14 cases, 56%), which is consistent with other larger reviews. Presentation in the head and neck (e.g. brain, eye, nose, and scalp) occurred more frequently (6 cases, 24%). No descriptive data analysis was performed to determine if our observations were significant. The majority of reports were originally described as proximal epithelioid sarcoma, but overall these remained a morphologically diverse group of cases that also included rhabdoid and mixed phenotypes.",
            "ntype": "p",
            "meta": {
                "created_by": "F1000XMLParser"
            }
        },
        {
            "ix": "9-662_v1_18",
            "content": "Table 3.",
            "ntype": "label",
            "meta": {
                "id": "T3",
                "caption": "Included rare sarcomas reported in single case reports, case series, or systematic reviews, 2000\u20132020. Inclusion criteria was as follows: ability to confirm an individual case patient was greater than 18 years of age; documentation of a loss of SMARCB1/INI1 expression by immunohistochemistry or genetic studies; and confirmed sarcomatous histologic tumor type. \u201c - \u201c denotes complete, reduced, or mosaic loss of SMARCB1/INI1 expression (exp.). M, male; F, female.",
                "created_by": "F1000XMLParser"
            }
        },
        {
            "ix": "9-662_v1_19",
            "content": "<table-wrap xmlns:mml=\"http://www.w3.org/1998/Math/MathML\" xmlns:xlink=\"http://www.w3.org/1999/xlink\" id=\"T3\" position=\"anchor\"> <caption> <title>Included rare sarcomas reported in single case reports, case series, or systematic reviews, 2000&#8211;2020.</title> <p>Inclusion criteria was as follows: ability to confirm an individual case patient was greater than 18 years of age; documentation of a loss of <italic>SMARCB1/INI1</italic> expression by immunohistochemistry or genetic studies; and confirmed sarcomatous histologic tumor type. &#8220; - &#8220; denotes complete, reduced, or mosaic loss of <italic>SMARCB1/INI1</italic> expression (exp.). M, male; F, female.</p> </caption> <table content-type=\"article-table\" frame=\"hsides\"> <thead> <tr> <th align=\"left\" valign=\"middle\">Article</th> <th align=\"center\" valign=\"middle\">PMID</th> <th align=\"center\" valign=\"middle\">Cases, <break/>no.</th> <th align=\"center\" valign=\"middle\">Age, <break/>Sex</th> <th align=\"center\" valign=\"middle\">Tumor site</th> <th align=\"center\" valign=\"middle\">SMARCB1/ INI1 <break/>exp.</th> <th align=\"left\" valign=\"middle\">Sarcoma morphology</th> </tr> </thead> <tbody> <tr> <td align=\"left\" valign=\"top\">Parker <italic>et al.</italic>, 2020 <sup> <xref ref-type=\"bibr\" rid=\"ref-42\">42</xref> </sup> </td> <td align=\"center\" valign=\"top\">32467817</td> <td align=\"center\" valign=\"top\">1</td> <td align=\"center\" valign=\"top\">56 M</td> <td align=\"center\" valign=\"top\">inguinal</td> <td align=\"center\" valign=\"top\">-</td> <td align=\"left\" valign=\"top\">epithelioid, rhabdoid</td> </tr> <tr> <td align=\"left\" valign=\"top\">Ahmad <italic>et al.</italic>, 2019 <sup> <xref ref-type=\"bibr\" rid=\"ref-93\">93</xref> </sup> </td> <td align=\"center\" valign=\"top\">31737506</td> <td align=\"center\" valign=\"top\">1</td> <td align=\"center\" valign=\"top\">27 M</td> <td align=\"center\" valign=\"top\">pleura</td> <td align=\"center\" valign=\"top\">-</td> <td align=\"left\" valign=\"top\">epithelioid</td> </tr> <tr> <td align=\"left\" valign=\"top\">Bodi <italic>et al.</italic>, 2018 <sup> <xref ref-type=\"bibr\" rid=\"ref-94\">94</xref> </sup> </td> <td align=\"center\" valign=\"top\">29541486</td> <td align=\"center\" valign=\"top\">1</td> <td align=\"center\" valign=\"top\">22 F</td> <td align=\"center\" valign=\"top\">brain</td> <td align=\"center\" valign=\"top\">-</td> <td align=\"left\" valign=\"top\">epithelioid, spindle-shaped</td> </tr> <tr> <td align=\"left\" valign=\"top\">Gurwale <italic>et al.</italic>, 2017 <sup> <xref ref-type=\"bibr\" rid=\"ref-95\">95</xref> </sup> </td> <td align=\"center\" valign=\"top\">-</td> <td align=\"center\" valign=\"top\">1</td> <td align=\"center\" valign=\"top\">18 F</td> <td align=\"center\" valign=\"top\">scalp</td> <td align=\"center\" valign=\"top\">-</td> <td align=\"left\" valign=\"top\">epithelioid</td> </tr> <tr> <td align=\"left\" valign=\"top\">Saha D <italic>et al.</italic>, 2016 <sup> <xref ref-type=\"bibr\" rid=\"ref-96\">96</xref> </sup> </td> <td align=\"center\" valign=\"top\">27045049</td> <td align=\"center\" valign=\"top\">1</td> <td align=\"center\" valign=\"top\">41 M</td> <td align=\"center\" valign=\"top\">lung</td> <td align=\"center\" valign=\"top\">-</td> <td align=\"left\" valign=\"top\">epithelioid</td> </tr> <tr> <td align=\"left\" valign=\"top\">Rego <italic>et al.</italic>, 2015 <sup> <xref ref-type=\"bibr\" rid=\"ref-97\">97</xref> </sup> </td> <td align=\"center\" valign=\"top\">25737787</td> <td align=\"center\" valign=\"top\">1</td> <td align=\"center\" valign=\"top\">34 F</td> <td align=\"center\" valign=\"top\">vulva</td> <td align=\"center\" valign=\"top\">-</td> <td align=\"left\" valign=\"top\">epithelioid, spindle-shaped</td> </tr> <tr> <td align=\"left\" valign=\"top\">Wetzel <italic>et al.</italic>, 2014 <sup> <xref ref-type=\"bibr\" rid=\"ref-98\">98</xref> </sup> </td> <td align=\"center\" valign=\"top\">24997629</td> <td align=\"center\" valign=\"top\">1</td> <td align=\"center\" valign=\"top\">51 F</td> <td align=\"center\" valign=\"top\">oral</td> <td align=\"center\" valign=\"top\">-</td> <td align=\"left\" valign=\"top\">rhabdoid</td> </tr> <tr> <td align=\"left\" valign=\"top\">Agaimy <italic>et al.</italic>, 2014 <sup> <xref ref-type=\"bibr\" rid=\"ref-99\">99</xref> </sup> </td> <td align=\"center\" valign=\"top\">24503755</td> <td align=\"center\" valign=\"top\">1</td> <td align=\"center\" valign=\"top\">66 M</td> <td align=\"center\" valign=\"top\">stomach</td> <td align=\"center\" valign=\"top\">-</td> <td align=\"left\" valign=\"top\">rhabdoid</td> </tr> <tr> <td align=\"left\" valign=\"top\">Madsen <italic>et al.</italic>, 2013 <sup> <xref ref-type=\"bibr\" rid=\"ref-100\">100</xref> </sup> </td> <td align=\"center\" valign=\"top\">24457248</td> <td align=\"center\" valign=\"top\">1</td> <td align=\"center\" valign=\"top\">45 M</td> <td align=\"center\" valign=\"top\">pleura</td> <td align=\"center\" valign=\"top\">-</td> <td align=\"left\" valign=\"top\">epithelioid</td> </tr> <tr> <td align=\"left\" valign=\"top\">Frank <italic>et al.</italic>, 2013 <sup> <xref ref-type=\"bibr\" rid=\"ref-101\">101</xref> </sup> </td> <td align=\"center\" valign=\"top\">24308011</td> <td align=\"center\" valign=\"top\">1</td> <td align=\"center\" valign=\"top\">43 M</td> <td align=\"center\" valign=\"top\">eye</td> <td align=\"center\" valign=\"top\">-</td> <td align=\"left\" valign=\"top\">epithelioid, spindle-shaped</td> </tr> <tr> <td align=\"center\" valign=\"top\"/> <td align=\"center\" valign=\"top\"/> <td align=\"center\" valign=\"top\">2</td> <td align=\"center\" valign=\"top\">71 F</td> <td align=\"center\" valign=\"top\">nasal</td> <td align=\"center\" valign=\"top\">-</td> <td align=\"left\" valign=\"top\">epithelioid</td> </tr> <tr> <td align=\"left\" valign=\"top\">Kim <italic>et al.</italic> 2012 <sup> <xref ref-type=\"bibr\" rid=\"ref-102\">102</xref> </sup> </td> <td align=\"center\" valign=\"top\">21724432</td> <td align=\"center\" valign=\"top\">1</td> <td align=\"center\" valign=\"top\">41 F</td> <td align=\"center\" valign=\"top\">vulva</td> <td align=\"center\" valign=\"top\">-</td> <td align=\"left\" valign=\"top\">epithelioid</td> </tr> <tr> <td align=\"left\" valign=\"top\">Mannan <italic>et al.</italic>, 2010 <sup> <xref ref-type=\"bibr\" rid=\"ref-103\">103</xref> </sup> </td> <td align=\"center\" valign=\"top\">19757197</td> <td align=\"center\" valign=\"top\">1</td> <td align=\"center\" valign=\"top\">47 M</td> <td align=\"center\" valign=\"top\">inguinal</td> <td align=\"center\" valign=\"top\">-</td> <td align=\"left\" valign=\"top\">epithelioid</td> </tr> <tr> <td align=\"left\" valign=\"top\">Takei <italic>et al.</italic>, 2010 <sup> <xref ref-type=\"bibr\" rid=\"ref-104\">104</xref> </sup> </td> <td align=\"center\" valign=\"top\">19911885</td> <td align=\"center\" valign=\"top\">1</td> <td align=\"center\" valign=\"top\">33 F</td> <td align=\"center\" valign=\"top\">brain</td> <td align=\"center\" valign=\"top\">-</td> <td align=\"left\" valign=\"top\">rhabdoid</td> </tr> <tr> <td align=\"center\" valign=\"top\"/> <td align=\"center\" valign=\"top\"/> <td align=\"center\" valign=\"top\">2</td> <td align=\"center\" valign=\"top\">79 M</td> <td align=\"center\" valign=\"top\">cecum</td> <td align=\"center\" valign=\"top\">-</td> <td align=\"left\" valign=\"top\">rhabdoid</td> </tr> <tr> <td align=\"left\" valign=\"top\">Raoux <italic>et al.</italic>, 2009 <sup> <xref ref-type=\"bibr\" rid=\"ref-105\">105</xref> </sup> </td> <td align=\"center\" valign=\"top\">19342946</td> <td align=\"center\" valign=\"top\">1</td> <td align=\"center\" valign=\"top\">31 F</td> <td align=\"center\" valign=\"top\">bone</td> <td align=\"center\" valign=\"top\">-</td> <td align=\"left\" valign=\"top\">epithelioid, spindle-shaped</td> </tr> <tr> <td align=\"left\" valign=\"top\">Robbens <italic>et al.</italic>, 2006 <sup> <xref ref-type=\"bibr\" rid=\"ref-106\">106</xref> </sup> </td> <td align=\"center\" valign=\"top\">16602014</td> <td align=\"center\" valign=\"top\">1</td> <td align=\"center\" valign=\"top\">19 M</td> <td align=\"center\" valign=\"top\">vertebra</td> <td align=\"center\" valign=\"top\">-</td> <td align=\"left\" valign=\"top\">epithelioid</td> </tr> <tr> <td align=\"left\" valign=\"top\">Sigauke <italic>et al.</italic>, 2006 <sup> <xref ref-type=\"bibr\" rid=\"ref-107\">107</xref> </sup> </td> <td align=\"center\" valign=\"top\">16528370</td> <td align=\"center\" valign=\"top\">1</td> <td align=\"center\" valign=\"top\">26 M</td> <td align=\"center\" valign=\"top\">wrist</td> <td align=\"center\" valign=\"top\">-</td> <td align=\"left\" valign=\"top\">epithelioid</td> </tr> <tr> <td align=\"center\" valign=\"top\"/> <td align=\"center\" valign=\"top\"/> <td align=\"center\" valign=\"top\">2</td> <td align=\"center\" valign=\"top\">26 M</td> <td align=\"center\" valign=\"top\">lymph </td> <td align=\"center\" valign=\"top\">-</td> <td align=\"left\" valign=\"top\">epithelioid</td> </tr> <tr> <td align=\"left\" valign=\"top\">Perry <italic>et al.</italic>, 2005 <sup> <xref ref-type=\"bibr\" rid=\"ref-108\">108</xref> </sup> </td> <td align=\"center\" valign=\"top\">15761491</td> <td align=\"center\" valign=\"top\">1</td> <td align=\"center\" valign=\"top\">29 M</td> <td align=\"center\" valign=\"top\">soft tissue</td> <td align=\"center\" valign=\"top\">-</td> <td align=\"left\" valign=\"top\">spindle-shaped</td> </tr> <tr> <td align=\"left\" valign=\"top\">Modena <italic>et al.</italic>, 2005 <sup> <xref ref-type=\"bibr\" rid=\"ref-50\">50</xref> </sup> </td> <td align=\"center\" valign=\"top\">15899790</td> <td align=\"center\" valign=\"top\">1</td> <td align=\"center\" valign=\"top\">31 F</td> <td align=\"center\" valign=\"top\">thigh</td> <td align=\"center\" valign=\"top\">-</td> <td align=\"left\" valign=\"top\">epithelioid</td> </tr> <tr> <td align=\"center\" valign=\"top\"/> <td align=\"center\" valign=\"top\"/> <td align=\"center\" valign=\"top\">2</td> <td align=\"center\" valign=\"top\">47 F</td> <td align=\"center\" valign=\"top\">perineum</td> <td align=\"center\" valign=\"top\">-</td> <td align=\"left\" valign=\"top\">rhabdoid</td> </tr> <tr> <td align=\"center\" valign=\"top\"/> <td align=\"center\" valign=\"top\"/> <td align=\"center\" valign=\"top\">3</td> <td align=\"center\" valign=\"top\">30 M</td> <td align=\"center\" valign=\"top\">spine</td> <td align=\"center\" valign=\"top\">-</td> <td align=\"left\" valign=\"top\">epithelioid</td> </tr> <tr> <td align=\"center\" valign=\"top\"/> <td align=\"center\" valign=\"top\"/> <td align=\"center\" valign=\"top\">4</td> <td align=\"center\" valign=\"top\">36 M</td> <td align=\"center\" valign=\"top\">spine</td> <td align=\"center\" valign=\"top\">-</td> <td align=\"left\" valign=\"top\">epithelioid, spindle-shaped</td> </tr> <tr> <td align=\"center\" valign=\"top\"/> <td align=\"center\" valign=\"top\"/> <td align=\"center\" valign=\"top\">5</td> <td align=\"center\" valign=\"top\">66 F</td> <td align=\"center\" valign=\"top\">inguinal</td> <td align=\"center\" valign=\"top\">-</td> <td align=\"left\" valign=\"top\">epithelioid, rhabdoid</td> </tr> </tbody> </table> </table-wrap>",
            "ntype": "table-wrap",
            "meta": {
                "id": "T3",
                "caption": "Included rare sarcomas reported in single case reports, case series, or systematic reviews, 2000\u20132020. Inclusion criteria was as follows: ability to confirm an individual case patient was greater than 18 years of age; documentation of a loss of SMARCB1/INI1 expression by immunohistochemistry or genetic studies; and confirmed sarcomatous histologic tumor type. \u201c - \u201c denotes complete, reduced, or mosaic loss of SMARCB1/INI1 expression (exp.). M, male; F, female.",
                "created_by": "F1000XMLParser"
            }
        },
        {
            "ix": "9-662_v1_20",
            "content": "Treatment",
            "ntype": "title",
            "meta": {
                "section": "4",
                "created_by": "F1000XMLParser"
            }
        },
        {
            "ix": "9-662_v1_21",
            "content": "Prior to, and still after, the discovery that SMARCB1/INI1-deficient tumors contribute to the large majority of soft tissue sarcomas, systemic cytotoxic agents have been used to treat this diverse group of neoplasms. Doxorubicin and ifosfamide have remained the mainstay of first-line treatment for advanced disease for the last few decades. Currently, the most widely used regimen for soft tissue sarcomas is termed AIM, which includes doxorubicin plus ifosfamide and mesna <REF-109> \u2013 <REF-111> . Therapies such as these, and other cytotoxic agents, exhibit intermediate to improved anti-cancer activity, and prolong survival in metastatic soft tissue sarcoma ( Table 4 ). However, refractory or progressive disease can occur. With the hopes of improving outcomes in patients who develop aggressive sarcomas, multiple new therapies are being introduced. Olaratumab, a monoclonal antibody that targets platelet-derived growth factor alpha and beta (PDGFRA/B), has been approved for first-line therapy in combination with doxorubicin due to improved progression and overall survival in sarcoma patients <REF-112> . The use of tyrosine kinase-inhibitors (TKIs) has transformed the treatment of advanced GIST. Imatinib, a TKI, as monotherapy is now approved for upfront treatment of metastatic GIST due to improved side effect profiles and outcomes in these patients <REF-113> \u2013 <REF-115> . Given its mechanism of action, imatinib is also approved for first-line treatment of the fibrosarcomatous variant of dermatofibrosarcoma protuberans <REF-116> , <REF-117> .",
            "ntype": "p",
            "meta": {
                "created_by": "F1000XMLParser"
            }
        },
        {
            "ix": "9-662_v1_22",
            "content": "Table 4.",
            "ntype": "label",
            "meta": {
                "id": "T4",
                "caption": "Approved first-line treatments for sarcomas. ORR, overall response rate; PFS, progression free survival; OS, overall survival; STS, soft tissue sarcoma; GIST, gastrointestinal stromal tumor; D, doxorubicine; I, ifosfamide; P, palifosfamide; E, Evofosfamide; T, trabectedin; O, Olaratumab; G, gemcitabine; Doc, docetaxel; NA, data not available.",
                "created_by": "F1000XMLParser"
            }
        },
        {
            "ix": "9-662_v1_23",
            "content": "<table-wrap xmlns:mml=\"http://www.w3.org/1998/Math/MathML\" xmlns:xlink=\"http://www.w3.org/1999/xlink\" id=\"T4\" position=\"anchor\"> <caption> <title>Approved first-line treatments for sarcomas.</title> <p>ORR, overall response rate; PFS, progression free survival; OS, overall survival; STS, soft tissue sarcoma; GIST, gastrointestinal stromal tumor; D, doxorubicine; I, ifosfamide; P, palifosfamide; E, Evofosfamide; T, trabectedin; O, Olaratumab; G, gemcitabine; Doc, docetaxel; NA, data not available.</p> </caption> <table content-type=\"article-table\" frame=\"hsides\"> <thead> <tr> <th align=\"center\" valign=\"middle\">Tumor</th> <th align=\"center\" valign=\"middle\">Drugs</th> <th align=\"center\" valign=\"middle\">Schedules</th> <th align=\"center\" valign=\"middle\">ORR <break/>(%)</th> <th align=\"center\" valign=\"middle\">PFS <break/>(months)</th> <th align=\"center\" valign=\"middle\">OS <break/>(months)</th> <th align=\"center\" valign=\"middle\">Reference</th> </tr> </thead> <tbody> <tr> <td align=\"left\" rowspan=\"10\">STS</td> <td align=\"left\" rowspan=\"5\">Doxorubicin <break/> <break/>Ifosfamide <break/> <break/>Evofosfamide <break/> <break/>Trabectedin <break/> <break/>Olaratumab</td> <td align=\"left\" valign=\"top\">D + I</td> <td align=\"left\" valign=\"top\">26</td> <td align=\"left\" valign=\"top\">7.4</td> <td align=\"left\" valign=\"top\">14.3</td> <td align=\"left\" valign=\"top\"> <sup> <xref ref-type=\"bibr\" rid=\"ref-128\">128</xref> </sup> </td> </tr> <tr> <td align=\"left\" valign=\"top\">D + P</td> <td align=\"left\" valign=\"top\">28.3</td> <td align=\"left\" valign=\"top\">6</td> <td align=\"left\" valign=\"top\">15.9</td> <td align=\"left\" valign=\"top\"> <sup> <xref ref-type=\"bibr\" rid=\"ref-129\">129</xref> </sup> </td> </tr> <tr> <td align=\"left\" valign=\"top\">D + E</td> <td align=\"left\" valign=\"top\">28.4</td> <td align=\"left\" valign=\"top\">6.3</td> <td align=\"left\" valign=\"top\">18.4</td> <td align=\"left\" valign=\"top\"> <sup> <xref ref-type=\"bibr\" rid=\"ref-130\">130</xref> </sup> </td> </tr> <tr> <td align=\"left\" valign=\"top\">D + T</td> <td align=\"left\" valign=\"top\">17</td> <td align=\"left\" valign=\"top\">5.7</td> <td align=\"left\" valign=\"top\">13.3</td> <td align=\"left\" valign=\"top\"> <sup> <xref ref-type=\"bibr\" rid=\"ref-131\">131</xref> </sup> </td> </tr> <tr> <td align=\"left\" valign=\"top\">D + O</td> <td align=\"left\" valign=\"top\">18.2</td> <td align=\"left\" valign=\"top\">6.6</td> <td align=\"left\" valign=\"top\">26.5</td> <td align=\"left\" valign=\"top\"> <sup> <xref ref-type=\"bibr\" rid=\"ref-112\">112</xref> </sup> </td> </tr> <tr> <td align=\"left\" valign=\"top\">Trabectedin</td> <td align=\"left\" valign=\"top\">monotherapy</td> <td align=\"left\" valign=\"top\">14.8</td> <td align=\"left\" valign=\"top\">2.8</td> <td align=\"left\" valign=\"top\">NA</td> <td align=\"left\" valign=\"top\"> <sup> <xref ref-type=\"bibr\" rid=\"ref-132\">132</xref> </sup> </td> </tr> <tr> <td align=\"left\" valign=\"top\">Aldoxorubicin</td> <td align=\"left\" valign=\"top\">monotherapy</td> <td align=\"left\" valign=\"top\">25</td> <td align=\"left\" valign=\"top\">5.6</td> <td align=\"left\" valign=\"top\">15.8</td> <td align=\"left\" valign=\"top\"> <sup> <xref ref-type=\"bibr\" rid=\"ref-133\">133</xref> </sup> </td> </tr> <tr> <td align=\"left\" valign=\"top\">Amrubicin</td> <td align=\"left\" valign=\"top\">monotherapy</td> <td align=\"left\" valign=\"top\">13</td> <td align=\"left\" valign=\"top\">5.8</td> <td align=\"left\" valign=\"top\">26</td> <td align=\"left\" valign=\"top\"> <sup> <xref ref-type=\"bibr\" rid=\"ref-134\">134</xref> </sup> </td> </tr> <tr> <td align=\"left\" valign=\"top\">Gemcitabine <break/> <break/>Docetaxel</td> <td align=\"left\" valign=\"top\">G + Doc</td> <td align=\"left\" valign=\"top\">58.6</td> <td align=\"left\" valign=\"top\">5.6</td> <td align=\"left\" valign=\"top\">14.7</td> <td align=\"left\" valign=\"top\"> <sup> <xref ref-type=\"bibr\" rid=\"ref-135\">135</xref> </sup> </td> </tr> <tr> <td align=\"left\" valign=\"top\">Brostacillin</td> <td align=\"left\" valign=\"top\">monotherapy</td> <td align=\"left\" valign=\"top\">3.9</td> <td align=\"left\" valign=\"top\">1.6</td> <td align=\"left\" valign=\"top\">NA</td> <td align=\"left\" valign=\"top\"> <sup> <xref ref-type=\"bibr\" rid=\"ref-136\">136</xref> </sup> </td> </tr> <tr> <td align=\"left\" valign=\"top\">GIST</td> <td align=\"left\" valign=\"top\">Imatinib</td> <td align=\"left\" valign=\"top\">monotherapy</td> <td align=\"left\" valign=\"top\">68.1</td> <td align=\"left\" valign=\"top\">18</td> <td align=\"left\" valign=\"top\">55</td> <td align=\"left\" valign=\"top\"> <sup> <xref ref-type=\"bibr\" rid=\"ref-113\">113</xref>&#8211; <xref ref-type=\"bibr\" rid=\"ref-115\">115</xref> </sup> </td> </tr> <tr> <td align=\"left\" valign=\"top\">Angiosarcoma</td> <td align=\"left\" valign=\"top\">Paclitaxel </td> <td align=\"left\" valign=\"top\">monotherapy</td> <td align=\"left\" valign=\"top\">NA</td> <td align=\"left\" valign=\"top\">4</td> <td align=\"left\" valign=\"top\">8</td> <td align=\"left\" valign=\"top\"> <sup> <xref ref-type=\"bibr\" rid=\"ref-137\">137</xref> </sup> </td> </tr> </tbody> </table> </table-wrap>",
            "ntype": "table-wrap",
            "meta": {
                "id": "T4",
                "caption": "Approved first-line treatments for sarcomas. ORR, overall response rate; PFS, progression free survival; OS, overall survival; STS, soft tissue sarcoma; GIST, gastrointestinal stromal tumor; D, doxorubicine; I, ifosfamide; P, palifosfamide; E, Evofosfamide; T, trabectedin; O, Olaratumab; G, gemcitabine; Doc, docetaxel; NA, data not available.",
                "created_by": "F1000XMLParser"
            }
        },
        {
            "ix": "9-662_v1_24",
            "content": "Additional TKIs have recently been introduced, with clinical trial data showing promise for their use in sarcomas. Sunitinib and regorafenib significantly improve overall survival in imatinib-resistant GIST patients <REF-118> . Pazopanib, a TKI that targets angiogenesis by inhibiting vascular endothelial growth factor receptor, PDGFRA/B, and KIT, has been shown to improve progression free survival in certain histologic types of sarcoma. This led to its approval for advanced, refractory non-lipomatous sarcoma <REF-119> , <REF-120> . Alveolar sarcomas appear to respond well to anti-angiogenetic sorafenib and cediranib <REF-121> , <REF-122> . In phase II studies tivozanib, which mechanism of action mimics pazopanib, exhibits promising anti-cancer activity in metastatic or nonresectable soft tissue sarcomas <REF-123> .",
            "ntype": "p",
            "meta": {
                "created_by": "F1000XMLParser"
            }
        },
        {
            "ix": "9-662_v1_25",
            "content": "Recently, much work studying the complex mechanisms involved in sarcoma tumorigenesis has revealed the potential for numerous new drug targets. Targeting mTOR by serine/threonine kinase inhibition has been widely studied. However, thus far either only equivocal or minor benefits have been shown with the administration of these agents <REF-124> . In contrast, phase II trial data is reassuring for the future use of palbociclib, a cyclin-dependent kinase 4 and 6 inhibitor approved in breast cancer, for liposarcoma <REF-125> , <REF-126> .",
            "ntype": "p",
            "meta": {
                "created_by": "F1000XMLParser"
            }
        },
        {
            "ix": "9-662_v1_26",
            "content": "Preliminary data from pre-clinical and phase I/II trials is encouraging for small molecule inhibitors, such as with MDM2-antagonists, histone deacetylase inhibitors, and histone methylation inhibitors <REF-124> . A possible breakthrough in small molecular inhibition is represented by the recent discovery of histone-lysine N-methyltransferase EZH2 upregulation in SMARCB1/INI1-deficient tumors <REF-127> . Given the defining characteristic of SMARCB1/INI1 deficiency in the nearly all soft tissue sarcomas, tazemetostat has emerged as a highly intriguing compound for its direct inhibition of histone-lysine N-methyltransferase EZH2 <REF-138> , <REF-139> . Another new agent that hopes to improve outcomes for patients with these rare and aggressive SMARCB1/INI1-deficient rhabdoid sarcomas comes from the proteasome inhibitor drug class. Ixazomib selectively targets proteasomes involved in protein anabolism and cellular apoptosis, whose activity is directly enhanced by the transcription factor MYC in SMARCB1/INI1 -deficient states. Currently, ixazomib plus gemcitabine and doxorubicin is being studied in the phase II trial setting for renal medullary carcinoma <REF-140> , <REF-141> .",
            "ntype": "p",
            "meta": {
                "created_by": "F1000XMLParser"
            }
        },
        {
            "ix": "9-662_v1_27",
            "content": "Data availability",
            "ntype": "title",
            "meta": {
                "section": "5",
                "created_by": "F1000XMLParser"
            }
        },
        {
            "ix": "9-662_v1_28",
            "content": "Underlying data",
            "ntype": "title",
            "meta": {
                "section": "5.1",
                "created_by": "F1000XMLParser"
            }
        },
        {
            "ix": "9-662_v1_29",
            "content": "No data are associated with this article.",
            "ntype": "p",
            "meta": {
                "created_by": "F1000XMLParser"
            }
        },
        {
            "ix": "9-662_v1_30",
            "content": "<REF-1> Abrams E Neigeborn L Carlson M : Molecular analysis of SNF2 and SNF5, genes required for expression of glucose-repressible genes in Saccharomyces cerevisiae. Mol Cell Biol. 1986 ; 6 ( 11 ): 3643 \u2013 3651 . 3540598 10.1128/mcb.6.11.3643 367125",
            "ntype": "ref",
            "meta": {
                "id": "ref-1",
                "created_by": "F1000XMLParser"
            }
        },
        {
            "ix": "9-662_v1_31",
            "content": "<REF-2> Kalpana GV Marmon S Wang W : Binding and stimulation of HIV-1 integrase by a human homolog of yeast transcription factor SNF5. Science. 1994 ; 266 ( 5193 ): 2002 \u2013 2006 . 7801128 10.1126/science.7801128",
            "ntype": "ref",
            "meta": {
                "id": "ref-2",
                "created_by": "F1000XMLParser"
            }
        },
        {
            "ix": "9-662_v1_32",
            "content": "<REF-3> Muchardt C Sardet C Bourachot B : A human protein with homology to Saccharomyces cerevisiae SNF5 interacts with the potential helicase hbrm. Nucleic Acids Res. 1995 ; 23 ( 7 ): 1127 \u2013 1132 . 7739891 10.1093/nar/23.7.1127 306820",
            "ntype": "ref",
            "meta": {
                "id": "ref-3",
                "created_by": "F1000XMLParser"
            }
        },
        {
            "ix": "9-662_v1_33",
            "content": "<REF-4> Hollmann TJ Hornick JL : INI1-deficient tumors: diagnostic features and molecular genetics. Am J Surg Pathol. 2011 ; 35 ( 10 ): e47 \u2013 63 . 21934399 10.1097/PAS.0b013e31822b325b",
            "ntype": "ref",
            "meta": {
                "id": "ref-4",
                "created_by": "F1000XMLParser"
            }
        },
        {
            "ix": "9-662_v1_34",
            "content": "<REF-5> Guidi CJ Sands AT Zambrowicz BP : Disruption of Ini1 leads to peri-implantation lethality and tumorigenesis in mice. Mol Cell Biol. 2001 ; 21 ( 10 ): 3598 \u2013 3603 . 11313485 10.1128/MCB.21.10.3598-3603.2001 100281",
            "ntype": "ref",
            "meta": {
                "id": "ref-5",
                "created_by": "F1000XMLParser"
            }
        },
        {
            "ix": "9-662_v1_35",
            "content": "<REF-6> Roberts CW Orkin SH : The SWI/SNF complex--chromatin and cancer. Nat Rev Cancer. 2004 ; 4 ( 2 ): 133 \u2013 142 . 14964309 10.1038/nrc1273",
            "ntype": "ref",
            "meta": {
                "id": "ref-6",
                "created_by": "F1000XMLParser"
            }
        },
        {
            "ix": "9-662_v1_36",
            "content": "<REF-8> Roberts CW Leroux MM Fleming MD : Highly penetrant, rapid tumorigenesis through conditional inversion of the tumor suppressor gene Snf5. Cancer Cell. 2002 ; 2 ( 5 ): 415 \u2013 425 . 12450796 10.1016/s1535-6108(02)00185-x",
            "ntype": "ref",
            "meta": {
                "id": "ref-8",
                "created_by": "F1000XMLParser"
            }
        },
        {
            "ix": "9-662_v1_37",
            "content": "<REF-9> Kohashi K Oda Y : Oncogenic roles of SMARCB1/INI1 and its deficient tumors. Cancer Sci. 2017 ; 108 ( 4 ): 547 \u2013 552 . 28109176 10.1111/cas.13173 5406539",
            "ntype": "ref",
            "meta": {
                "id": "ref-9",
                "created_by": "F1000XMLParser"
            }
        },
        {
            "ix": "9-662_v1_38",
            "content": "<REF-10> Ferrari A Sultan I Huang TT : Soft tissue sarcoma across the age spectrum: a population-based study from the Surveillance Epidemiology and End Results database. Pediatr Blood Cancer.. 2011 ; 57 ( 6 ): 943 \u2013 9 . 21793180 10.1002/pbc.23252 4261144",
            "ntype": "ref",
            "meta": {
                "id": "ref-10",
                "created_by": "F1000XMLParser"
            }
        },
        {
            "ix": "9-662_v1_39",
            "content": "<REF-12> Shonka NA Armstrong TS Prabhu SS : Atypical teratoid/rhabdoid tumors in adults: a case report and treatment-focused review. J Clin Med Res. 2011 ; 3 ( 2 ): 85 \u2013 92 . 21811535 10.4021/jocmr535w 3140928",
            "ntype": "ref",
            "meta": {
                "id": "ref-12",
                "created_by": "F1000XMLParser"
            }
        },
        {
            "ix": "9-662_v1_40",
            "content": "<REF-13> Doyle LA : Malignant rhabdoid tumor: Pathology of Human Disease. Academic press; 2014 .",
            "ntype": "ref",
            "meta": {
                "id": "ref-13",
                "created_by": "F1000XMLParser"
            }
        },
        {
            "ix": "9-662_v1_41",
            "content": "<REF-14> Horazdovsky R Manivel JC Cheng EY : Successful salvage and long-term survival after recurrent malignant rhabdoid tumor. Sarcoma. 2007 ; 2007 : 53549 . 17671630 10.1155/2007/53549 1920592",
            "ntype": "ref",
            "meta": {
                "id": "ref-14",
                "created_by": "F1000XMLParser"
            }
        },
        {
            "ix": "9-662_v1_42",
            "content": "<REF-17> Needs T Fillman EP : Cancer, Epithelioid Sarcoma. StatPearls. Treasure Island (FL): StatPearls. 2020 . 30422506",
            "ntype": "ref",
            "meta": {
                "id": "ref-17",
                "created_by": "F1000XMLParser"
            }
        },
        {
            "ix": "9-662_v1_43",
            "content": "<REF-19> Shetty A Matrana MR : Renal medullary carcinoma: a case report and brief review of the literature. Ochsner J. 2014 ; 14 ( 2 ): 270 \u2013 5 . 24940141 4052598",
            "ntype": "ref",
            "meta": {
                "id": "ref-19",
                "created_by": "F1000XMLParser"
            }
        },
        {
            "ix": "9-662_v1_44",
            "content": "<REF-26> Beccaria K Sainte-Rose C Zerah M : Paediatric Chordomas. Orphanet J Rare Dis. 2015 ; 10 : 116 . 26391590 10.1186/s13023-015-0340-8 4578760",
            "ntype": "ref",
            "meta": {
                "id": "ref-26",
                "created_by": "F1000XMLParser"
            }
        },
        {
            "ix": "9-662_v1_45",
            "content": "<REF-35> Morgan J Raut CP Duensing A : Epidemiology, classification, clinical presentation, prognostic features, and diagnostic work-up of gastrointestinal stromal tumors (GIST). UpToDate. 2019 . Reference Source",
            "ntype": "ref",
            "meta": {
                "id": "ref-35",
                "created_by": "F1000XMLParser"
            }
        },
        {
            "ix": "9-662_v1_46",
            "content": "<REF-36> DeMatteo RP Lewis JJ Leung D : Two hundred gastrointestinal stromal tumors: recurrence patterns and prognostic factors for survival. Ann Surg. 2000 ; 231 ( 1 ): 51 \u2013 58 . 10636102 10.1097/00000658-200001000-00008 1420965",
            "ntype": "ref",
            "meta": {
                "id": "ref-36",
                "created_by": "F1000XMLParser"
            }
        },
        {
            "ix": "9-662_v1_47",
            "content": "<REF-41> Pawel BR : SMARCB1-deficient Tumors of Childhood: A Practical Guide. Pediatr Dev Pathol. 2018 ; 21 ( 1 ): 6 \u2013 28 . 29280680 10.1177/1093526617749671",
            "ntype": "ref",
            "meta": {
                "id": "ref-41",
                "created_by": "F1000XMLParser"
            }
        },
        {
            "ix": "9-662_v1_48",
            "content": "<REF-42> Parker NA Al-Obaidi A Lalich D : SMARCB1/INI1-Deficient Extrarenal Rhabdoid Tumor: A Case Report of a Rare and Aggressive Soft Tissue Sarcoma. Cureus. 2020 ; 12 ( 5 ): e8273 . 32467817 10.7759/cureus.8273 7250519",
            "ntype": "ref",
            "meta": {
                "id": "ref-42",
                "created_by": "F1000XMLParser"
            }
        },
        {
            "ix": "9-662_v1_49",
            "content": "<REF-49> Zhao G Na R Yang Y : Pure malignant rhabdoid tumor of the left kidney in an adult: A case report and review of the literature. Oncol Lett. 2013 ; 5 ( 5 ): 1481 \u2013 1484 . 23761028 10.3892/ol.2013.1207 3678854",
            "ntype": "ref",
            "meta": {
                "id": "ref-49",
                "created_by": "F1000XMLParser"
            }
        },
        {
            "ix": "9-662_v1_50",
            "content": "<REF-50> Modena P Lualdi E Facchinetti F : SMARCB1/INI1 tumor suppressor gene is frequently inactivated in epithelioid sarcomas. Cancer Res.. 2005 ; 65 ( 10 ): 4012 \u2013 9 . 15899790 10.1158/0008-5472.CAN-04-3050",
            "ntype": "ref",
            "meta": {
                "id": "ref-50",
                "created_by": "F1000XMLParser"
            }
        },
        {
            "ix": "9-662_v1_51",
            "content": "<REF-51> Margol AS Judkins AR : Pathology and diagnosis of SMARCB1-deficient tumors. Cancer Genet. 2014 ; 207 ( 9 ): 358 \u2013 64 . 25246033 10.1016/j.cancergen.2014.07.004",
            "ntype": "ref",
            "meta": {
                "id": "ref-51",
                "created_by": "F1000XMLParser"
            }
        },
        {
            "ix": "9-662_v1_52",
            "content": "<REF-52> Ng WK Toe BP Lau HY : Malignant Rhabdoid Tumor of the Mediastinum: A Case Report and Literature Review. J Clin Imaging Sci. 2019 ; 9 : 7 . 31448158 10.25259/JCIS-9-7 6702892",
            "ntype": "ref",
            "meta": {
                "id": "ref-52",
                "created_by": "F1000XMLParser"
            }
        },
        {
            "ix": "9-662_v1_53",
            "content": "<REF-53> Gupta RK Batra VV Das MC : Malignant extra-renal rhabdoid tumor with unusual presentation: A report of two cases. J Cancer Res Ther. 2015 ; 11 ( 4 ): 963 \u2013 6 . 26881557 10.4103/0973-1482.163668",
            "ntype": "ref",
            "meta": {
                "id": "ref-53",
                "created_by": "F1000XMLParser"
            }
        },
        {
            "ix": "9-662_v1_54",
            "content": "<REF-54> Hoot AC Russo P Judkins AR : Immunohistochemical analysis of hSNF5/INI1 distinguishes renal and extra-renal malignant rhabdoid tumors from other pediatric soft tissue tumors. Am J Surg Pathol.. 2004 ; 28 ( 11 ): 1485 \u2013 91 . 15489652 10.1097/01.pas.0000141390.14548.34",
            "ntype": "ref",
            "meta": {
                "id": "ref-54",
                "created_by": "F1000XMLParser"
            }
        },
        {
            "ix": "9-662_v1_55",
            "content": "<REF-55> Chbani L Guillou L Terrier P : Epithelioid sarcoma: a clinicopathologic and immunohistochemical analysis of 106 cases from the French sarcoma group. Am J Clin Pathol. 2009 ; 131 ( 2 ): 222 \u2013 227 . 19141382 10.1309/AJCPU98ABIPVJAIV",
            "ntype": "ref",
            "meta": {
                "id": "ref-55",
                "created_by": "F1000XMLParser"
            }
        },
        {
            "ix": "9-662_v1_56",
            "content": "<REF-56> Kohashi K Tanaka Y Kishimoto H : Reclassification of rhabdoid tumor and pediatric undifferentiated/unclassified sarcoma with complete loss of SMARCB1/INI1 protein expression: three subtypes of rhabdoid tumor according to their histological features. Mod Pathol. 2016 ; 29 ( 10 ): 1232 \u2013 1242 . 10.1038/modpathol.2016.106",
            "ntype": "ref",
            "meta": {
                "id": "ref-56",
                "created_by": "F1000XMLParser"
            }
        },
        {
            "ix": "9-662_v1_57",
            "content": "<REF-57> Zhang XW Deng YJ Zhou L : Epithelioid sarcoma of the scalp: a case report and literature review. Int J Clin Exp Pathol. 2019 ; 12 ( 10 ): 3908 \u2013 3914 . 31933781 6949740",
            "ntype": "ref",
            "meta": {
                "id": "ref-57",
                "created_by": "F1000XMLParser"
            }
        },
        {
            "ix": "9-662_v1_58",
            "content": "<REF-92> Spillane AJ Thomas JM Fisher C : Epithelioid sarcoma: the clinicopathological complexities of this rare soft tissue sarcoma. Ann Surg Oncol. 2000 ; 7 ( 3 ): 218 \u2013 225 . 10791853 10.1007/BF02523657",
            "ntype": "ref",
            "meta": {
                "id": "ref-92",
                "created_by": "F1000XMLParser"
            }
        },
        {
            "ix": "9-662_v1_59",
            "content": "<REF-93> Ahmad Z Stanazai Q Wright S : Primary pleural epithelioid sarcoma of the proximal type: a diagnostic and therapeutic challenge. Transl Lung Cancer Res. 2019 ; 8 ( 5 ): 700 \u2013 705 . 31737506 10.21037/tlcr.2019.09.16 6835107",
            "ntype": "ref",
            "meta": {
                "id": "ref-93",
                "created_by": "F1000XMLParser"
            }
        },
        {
            "ix": "9-662_v1_60",
            "content": "<REF-108> Perry A Fuller CE Judkins AR : INI1 expression is retained in composite rhabdoid tumors, including rhabdoid meningiomas. Mod Pathol. 2005 ; 18 ( 7 ): 951 \u2013 958 . 15761491 10.1038/modpathol.3800375",
            "ntype": "ref",
            "meta": {
                "id": "ref-108",
                "created_by": "F1000XMLParser"
            }
        },
        {
            "ix": "9-662_v1_61",
            "content": "<REF-109> Edmonson JH Ryan LM Blum RH : Randomized comparison of doxorubicin alone versus ifosfamide plus doxorubicin or mitomycin, doxorubicin, and cisplatin against advanced soft tissue sarcomas. J Clin Oncol. 1993 ; 11 ( 7 ): 1269 \u2013 75 . 8315424 10.1200/JCO.1993.11.7.1269",
            "ntype": "ref",
            "meta": {
                "id": "ref-109",
                "created_by": "F1000XMLParser"
            }
        },
        {
            "ix": "9-662_v1_62",
            "content": "<REF-111> Worden FP Taylor JM Biermann JS : Randomized phase II evaluation of 6 g/m 2 of ifosfamide plus doxorubicin and granulocyte colony-stimulating factor (G-CSF) compared with 12 g/m 2 of ifosfamide plus doxorubicin and G-CSF in the treatment of poor-prognosis soft tissue sarcoma. J Clin Oncol. 2005 ; 23 ( 1 ): 105 \u2013 12 . 15625365 10.1200/JCO.2005.05.108",
            "ntype": "ref",
            "meta": {
                "id": "ref-111",
                "created_by": "F1000XMLParser"
            }
        },
        {
            "ix": "9-662_v1_63",
            "content": "<REF-112> Tap WD Jones RL Van Tine BA : Olaratumab and doxorubicin versus doxorubicin alone for treatment of soft-tissue sarcoma: an open-label phase 1b and randomised phase 2 trial . [published correction appears in Lancet. 2016 Jul 30; 388(10043):464]. Lancet. 2016 ; 388 ( 10043 ): 488 \u2013 497 . 27291997 10.1016/S0140-6736(16)30587-6 5647653",
            "ntype": "ref",
            "meta": {
                "id": "ref-112",
                "created_by": "F1000XMLParser"
            }
        },
        {
            "ix": "9-662_v1_64",
            "content": "<REF-113> van Oosterom AT Judson I Verweij J : Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumours: a phase I study. Lancet. 2001 ; 358 ( 9291 ): 1421 \u2013 1423 . 11705489 10.1016/s0140-6736(01)06535-7",
            "ntype": "ref",
            "meta": {
                "id": "ref-113",
                "created_by": "F1000XMLParser"
            }
        },
        {
            "ix": "9-662_v1_65",
            "content": "<REF-115> Blanke CD Rankin C Demetri GD : Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033. J Clin Oncol. 2008 ; 26 ( 4 ): 626 \u2013 632 . 18235122 10.1200/JCO.2007.13.4452",
            "ntype": "ref",
            "meta": {
                "id": "ref-115",
                "created_by": "F1000XMLParser"
            }
        },
        {
            "ix": "9-662_v1_66",
            "content": "<REF-116> Rutkowski P Van Glabbeke M Rankin CJ : Imatinib mesylate in advanced dermatofibrosarcoma protuberans: pooled analysis of two phase II clinical trials. J Clin Oncol. 2010 ; 28 ( 10 ): 1772 \u2013 1779 . 20194851 10.1200/JCO.2009.25.7899 3040044",
            "ntype": "ref",
            "meta": {
                "id": "ref-116",
                "created_by": "F1000XMLParser"
            }
        },
        {
            "ix": "9-662_v1_67",
            "content": "<REF-117> Stacchiotti S Pantaleo MA Negri T : Efficacy and Biological Activity of Imatinib in Metastatic Dermatofibrosarcoma Protuberans (DFSP). Clin Cancer Res. 2016 ; 22 ( 4 ): 837 \u2013 846 . 26261104 10.1158/1078-0432.CCR-15-1243",
            "ntype": "ref",
            "meta": {
                "id": "ref-117",
                "created_by": "F1000XMLParser"
            }
        },
        {
            "ix": "9-662_v1_68",
            "content": "<REF-118> Call JW Wang Y Montoya D : Survival in advanced GIST has improved over time and correlates with increased access to post-imatinib tyrosine kinase inhibitors: results from Life Raft Group Registry . [published correction appears in Clin Sarcoma Res. 2019 May 7;9:7]. Clin Sarcoma Res. 2019 ; 9 : 4 . 30984366 10.1186/s13569-019-0114-5 6446260",
            "ntype": "ref",
            "meta": {
                "id": "ref-118",
                "created_by": "F1000XMLParser"
            }
        },
        {
            "ix": "9-662_v1_69",
            "content": "<REF-119> van der Graaf WTA Blay JY Chawla SP : Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet. 2012 ; 379 ( 9829 ): 1879 \u2013 86 . 22595799 10.1016/S0140-6736(12)60651-5",
            "ntype": "ref",
            "meta": {
                "id": "ref-119",
                "created_by": "F1000XMLParser"
            }
        },
        {
            "ix": "9-662_v1_70",
            "content": "<REF-120> Sleijfer S Ray-Coquard I Papai Z : Pazopanib, a multikinase angiogenesis inhibitor, in patients with relapsed or refractory advanced soft tissue sarcoma: a phase II study from the European organisation for research and treatment of cancer-soft tissue and bone sarcoma group (EORTC study 62043). J Clin Oncol. 2009 ; 27 ( 19 ): 3126 \u2013 32 . 19451427 10.1200/JCO.2008.21.3223",
            "ntype": "ref",
            "meta": {
                "id": "ref-120",
                "created_by": "F1000XMLParser"
            }
        },
        {
            "ix": "9-662_v1_71",
            "content": "<REF-121> Ray-Coquard I Italiano A Bompas E : Sorafenib for Patients With Advanced Angiosarcoma: A Phase II Trial From the French Sarcoma Group (GSF/GETO). Oncologist. 2012 ; 17 ( 2 ): 260 \u2013 266 . 22285963 10.1634/theoncologist.2011-0237 3286175",
            "ntype": "ref",
            "meta": {
                "id": "ref-121",
                "created_by": "F1000XMLParser"
            }
        },
        {
            "ix": "9-662_v1_72",
            "content": "<REF-122> Kummar S Allen D Monks A : Cediranib for Metastatic Alveolar Soft Part Sarcoma. J Clin Oncol. 2013 ; 31 ( 18 ): 2296 \u2013 2302 . 23630200 10.1200/JCO.2012.47.4288 3677840",
            "ntype": "ref",
            "meta": {
                "id": "ref-122",
                "created_by": "F1000XMLParser"
            }
        },
        {
            "ix": "9-662_v1_73",
            "content": "<REF-123> Agulnik M Costa RLB Milhem M : A Phase II Study of Tivozanib in Patients With Metastatic and Nonresectable Soft-Tissue Sarcomas. Ann Oncol. 2017 ; 28 ( 1 ): 121 \u2013 127 . 27771610 10.1093/annonc/mdw444 6246191",
            "ntype": "ref",
            "meta": {
                "id": "ref-123",
                "created_by": "F1000XMLParser"
            }
        },
        {
            "ix": "9-662_v1_74",
            "content": "<REF-124> Frezza AM Stacchiotti S Gronchi A : Systemic Treatment in Advanced Soft Tissue Sarcoma: What Is Standard, What Is New. BMC Med. 2017 ; 15 ( 1 ): 109 . 28571564 10.1186/s12916-017-0872-y 5455204",
            "ntype": "ref",
            "meta": {
                "id": "ref-124",
                "created_by": "F1000XMLParser"
            }
        },
        {
            "ix": "9-662_v1_75",
            "content": "<REF-125> Binh MB Sastre-Garau X Guillou L : MDM2 and CDK4 Immunostainings Are Useful Adjuncts in Diagnosing Well-Differentiated and Dedifferentiated Liposarcoma Subtypes: A Comparative Analysis of 559 Soft Tissue Neoplasms With Genetic Data. Am J Surg Pathol. 2005 ; 29 ( 10 ): 1340 \u2013 1347 . 16160477 10.1097/01.pas.0000170343.09562.39",
            "ntype": "ref",
            "meta": {
                "id": "ref-125",
                "created_by": "F1000XMLParser"
            }
        },
        {
            "ix": "9-662_v1_76",
            "content": "<REF-126> Dickson MA Tap WD Keohan ML : Phase II trial of the CDK4 inhibitor PD0332991 in patients with advanced CDK4 -amplified well-differentiated or dedifferentiated liposarcoma. J Clin Oncol. 2013 ; 31 ( 16 ): 2024 \u2013 8 . 23569312 10.1200/JCO.2012.46.5476 3661937",
            "ntype": "ref",
            "meta": {
                "id": "ref-126",
                "created_by": "F1000XMLParser"
            }
        },
        {
            "ix": "9-662_v1_77",
            "content": "<REF-127> Wilson BG Wang X Shen X : Epigenetic antagonism between polycomb and SWI/SNF complexes during oncogenic transformation . [published correction appears in Cancer Cell. 2011 Jan 18; 19(1): 153] Cancer Cell. 2010 ; 18 ( 4 ): 316 \u2013 28 . 20951942 10.1016/j.ccr.2010.09.006 2957473",
            "ntype": "ref",
            "meta": {
                "id": "ref-127",
                "created_by": "F1000XMLParser"
            }
        },
        {
            "ix": "9-662_v1_78",
            "content": "<REF-138> Agulnik M Tannir NM Pressey JG : A phase II, multicenter study of the EZH2 inhibitor tazemetostat in adult subjects with INI1-negative tumors or relapsed/refractory synovial sarcoma. J Clin Oncol. 2016 ; 34 ( 15_suppl ): TPS11071 \u2013 TPS11071 . (suppl; abstr TPS11071). 10.1200/JCO.2016.34.15_suppl.TPS11071",
            "ntype": "ref",
            "meta": {
                "id": "ref-138",
                "created_by": "F1000XMLParser"
            }
        },
        {
            "ix": "9-662_v1_79",
            "content": "<REF-139> Wilson BG Wang X Shen X : Epigenetic antagonism between polycomb and SWI/SNF complexes during oncogenic transformation . [published correction appears in Cancer Cell. 2011 Jan 18; 19(1): 153] Cancer Cell. 2010 ; 18 ( 4 ): 316 \u2013 28 . 20951942 10.1016/j.ccr.2010.09.006 2957473",
            "ntype": "ref",
            "meta": {
                "id": "ref-139",
                "created_by": "F1000XMLParser"
            }
        },
        {
            "ix": "9-662_v1_80",
            "content": "<REF-140> Msaouel P Carugo A Genovese G : Targeting proteostasis and autophagy in SMARCB1-deficient malignancies: where next? Oncotarget. 2019 ; 10 ( 40 ): 3979 \u2013 3981 . 31258836 10.18632/oncotarget.26970 6592295",
            "ntype": "ref",
            "meta": {
                "id": "ref-140",
                "created_by": "F1000XMLParser"
            }
        },
        {
            "ix": "9-662_v1_81",
            "content": "<REF-141> Msaouel P Slack-Tidwell R Genovese G : Phase II trial of ixazomib combined with gemcitabine and doxorubicin in patients with SMARCB1-deficient kidney malignancies. J Clin Oncol. 2019 ; 37 ( 7_suppl ): (suppl; abstr TPS678\u2013TPS678). 10.1200/JCO.2019.37.7_suppl.TPS678",
            "ntype": "ref",
            "meta": {
                "id": "ref-141",
                "created_by": "F1000XMLParser"
            }
        }
    ],
    "span_nodes": [
        {
            "ix": "9-662_v1_0@0",
            "content": "SMARCB1/INI1-deficient tumors of adulthood",
            "ntype": "s",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            },
            "src_ix": "9-662_v1_0",
            "start": 0,
            "end": 41,
            "label": {}
        },
        {
            "ix": "9-662_v1_1@0",
            "content": "Abstract",
            "ntype": "s",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            },
            "src_ix": "9-662_v1_1",
            "start": 0,
            "end": 7,
            "label": {}
        },
        {
            "ix": "9-662_v1_2@0",
            "content": "The SMARCB1/INI1 gene was first discovered in the mid-1990\u2019s, and since then it has been revealed that loss of function mutations in this gene result in aggressive rhabdoid tumors.",
            "ntype": "s",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            },
            "src_ix": "9-662_v1_2",
            "start": 0,
            "end": 179,
            "label": {}
        },
        {
            "ix": "9-662_v1_2@1",
            "content": "Recently, the term \u201crhabdoid tumor\u201d has become synonymous with decreased SMARCB1/INI1 expression.",
            "ntype": "s",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            },
            "src_ix": "9-662_v1_2",
            "start": 181,
            "end": 277,
            "label": {}
        },
        {
            "ix": "9-662_v1_2@2",
            "content": "When genetic aberrations in the SMARCB1/INI1 gene occur, the result can cause reduced, complete loss, and mosaic expression.",
            "ntype": "s",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            },
            "src_ix": "9-662_v1_2",
            "start": 279,
            "end": 402,
            "label": {}
        },
        {
            "ix": "9-662_v1_2@3",
            "content": "Although SMARCB1/INI1-deficient tumors are predominantly sarcomas, this is a diverse group of tumors with mixed phenotypes, which can often make the diagnosis challenging.",
            "ntype": "s",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            },
            "src_ix": "9-662_v1_2",
            "start": 404,
            "end": 574,
            "label": {}
        },
        {
            "ix": "9-662_v1_2@4",
            "content": "Prognosis for these aggressive tumors is often poor.",
            "ntype": "s",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            },
            "src_ix": "9-662_v1_2",
            "start": 576,
            "end": 627,
            "label": {}
        },
        {
            "ix": "9-662_v1_2@5",
            "content": "Moreover, refractory and relapsing progressive disease is common.",
            "ntype": "s",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            },
            "src_ix": "9-662_v1_2",
            "start": 629,
            "end": 693,
            "label": {}
        },
        {
            "ix": "9-662_v1_2@6",
            "content": "As a result, accurate and timely diagnosis is imperative.",
            "ntype": "s",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            },
            "src_ix": "9-662_v1_2",
            "start": 695,
            "end": 751,
            "label": {}
        },
        {
            "ix": "9-662_v1_2@7",
            "content": "Despite the SMARCB1/INI1 gene itself and its implications in tumorigenesis being discovered over two decades ago, there is a paucity of rhabdoid tumor cases reported in the literature that detail SMARCB1/INI1 expression.",
            "ntype": "s",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            },
            "src_ix": "9-662_v1_2",
            "start": 753,
            "end": 972,
            "label": {}
        },
        {
            "ix": "9-662_v1_2@8",
            "content": "Much work remains if we hope to provide additional therapeutic strategies for patients with aggressive SMARCB1/INI1-deficient tumors.",
            "ntype": "s",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            },
            "src_ix": "9-662_v1_2",
            "start": 974,
            "end": 1106,
            "label": {}
        },
        {
            "ix": "9-662_v1_3@0",
            "content": "History of the SMARCB1/INI1 Gene",
            "ntype": "s",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            },
            "src_ix": "9-662_v1_3",
            "start": 0,
            "end": 31,
            "label": {}
        },
        {
            "ix": "9-662_v1_4@0",
            "content": "SWI/SNF-related matrix-associated actin-dependent regulator of chromatin subfamily B member 1 (SMARCB1), also known as integrase interactor 1 (INI1), is a crucial component of a chromatin-remodeling protein complex.",
            "ntype": "s",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            },
            "src_ix": "9-662_v1_4",
            "start": 0,
            "end": 214,
            "label": {}
        },
        {
            "ix": "9-662_v1_4@1",
            "content": "SMARCB1/INI1 was first identified in yeast in the late 1980\u2019s <REF-1> .",
            "ntype": "s",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            },
            "src_ix": "9-662_v1_4",
            "start": 216,
            "end": 286,
            "label": {}
        },
        {
            "ix": "9-662_v1_4@2",
            "content": "By 1994, its human homologue was isolated in fibroblast cells <REF-2> , <REF-3> .",
            "ntype": "s",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            },
            "src_ix": "9-662_v1_4",
            "start": 288,
            "end": 368,
            "label": {}
        },
        {
            "ix": "9-662_v1_4@3",
            "content": "Subsequent molecular investigations showed this nuclear protein complex enhances DNA transcription by interactions with HIV-1 integrase <REF-2> .",
            "ntype": "s",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            },
            "src_ix": "9-662_v1_4",
            "start": 370,
            "end": 514,
            "label": {}
        },
        {
            "ix": "9-662_v1_4@4",
            "content": "Nuclear SMARCB1/INI1 exists ubiquitously in all normal cells, and acts as a tumor suppressor gene <REF-4> .",
            "ntype": "s",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            },
            "src_ix": "9-662_v1_4",
            "start": 516,
            "end": 622,
            "label": {}
        },
        {
            "ix": "9-662_v1_4@5",
            "content": "It was revealed in the early 2000\u2019s by studies in mice that biallelic knockout of the SMARCB1/INI1 gene resulted in early lethality <REF-5> .",
            "ntype": "s",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            },
            "src_ix": "9-662_v1_4",
            "start": 624,
            "end": 764,
            "label": {}
        },
        {
            "ix": "9-662_v1_4@6",
            "content": "Mice with heterozygous loss before birth, or who had later conditional single-allele knockout after birth, of SMARCB1/INI1 developed aggressive rhabdoid tumors <REF-6> \u2013 <REF-8> .",
            "ntype": "s",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            },
            "src_ix": "9-662_v1_4",
            "start": 766,
            "end": 944,
            "label": {}
        },
        {
            "ix": "9-662_v1_4@7",
            "content": "Since its discovery, much work has revealed this chromatin-remodeling protein has crucial roles in multiple signaling pathways that function to suppress tumorigenesis and tumor growth <REF-9> .",
            "ntype": "s",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            },
            "src_ix": "9-662_v1_4",
            "start": 946,
            "end": 1138,
            "label": {}
        },
        {
            "ix": "9-662_v1_4@8",
            "content": "Although these pathways are highly complex, the development and use of targeted anti-cancer therapies has practically become ubiquitous for nearly all solid tumors.",
            "ntype": "s",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            },
            "src_ix": "9-662_v1_4",
            "start": 1140,
            "end": 1303,
            "label": {}
        },
        {
            "ix": "9-662_v1_4@9",
            "content": "Thus, continued investigations are needed if we hope to provide additional therapeutic strategies for patients with aggressive SMARCB1/INI1-deficient tumors <REF-9> .",
            "ntype": "s",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            },
            "src_ix": "9-662_v1_4",
            "start": 1305,
            "end": 1470,
            "label": {}
        },
        {
            "ix": "9-662_v1_5@0",
            "content": "Interestingly, the genetic signatures of SMARCB1/INI1-deficient tumors are far from monotonous.",
            "ntype": "s",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            },
            "src_ix": "9-662_v1_5",
            "start": 0,
            "end": 94,
            "label": {}
        },
        {
            "ix": "9-662_v1_5@1",
            "content": "Three distinct patterns of abnormal SMARCB1/INI1 gene expression have been identified \u2013 reduced, complete loss, and mosaic <REF-9> .",
            "ntype": "s",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            },
            "src_ix": "9-662_v1_5",
            "start": 96,
            "end": 227,
            "label": {}
        },
        {
            "ix": "9-662_v1_6@0",
            "content": "Epidemiology, clinical, prognosis",
            "ntype": "s",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            },
            "src_ix": "9-662_v1_6",
            "start": 0,
            "end": 32,
            "label": {}
        },
        {
            "ix": "9-662_v1_7@0",
            "content": "Complete loss of SMARCB1/INI1 expression has been linked to a number of pediatric and adult sarcomas ( Table 1 ).",
            "ntype": "s",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            },
            "src_ix": "9-662_v1_7",
            "start": 0,
            "end": 112,
            "label": {}
        },
        {
            "ix": "9-662_v1_7@1",
            "content": "Malignant rhabdoid tumor (MRT) and epithelioid sarcoma (ES) both result from biallelic deletions or mutations causing a complete loss of SMARCB1/INI1 expression <REF-41> .",
            "ntype": "s",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            },
            "src_ix": "9-662_v1_7",
            "start": 114,
            "end": 284,
            "label": {}
        },
        {
            "ix": "9-662_v1_7@2",
            "content": "Commonly arising before the age of three years old, MRTs are considered one of the most aggressive childhood neoplasms associated with high mortality <REF-41> .",
            "ntype": "s",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            },
            "src_ix": "9-662_v1_7",
            "start": 286,
            "end": 445,
            "label": {}
        },
        {
            "ix": "9-662_v1_7@3",
            "content": "MRTs have been reported in adults <REF-42> \u2013 <REF-49> .",
            "ntype": "s",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            },
            "src_ix": "9-662_v1_7",
            "start": 447,
            "end": 501,
            "label": {}
        },
        {
            "ix": "9-662_v1_7@4",
            "content": "Based on MRT of adulthood being primarily reported anecdotally, estimated rates of incidence remain unclear.",
            "ntype": "s",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            },
            "src_ix": "9-662_v1_7",
            "start": 503,
            "end": 610,
            "label": {}
        },
        {
            "ix": "9-662_v1_7@5",
            "content": "Data concerning the 5-year survival rate for MRT in adults is difficult to determine as well, as various percentages have been reported in literature <REF-13> , <REF-14> .",
            "ntype": "s",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            },
            "src_ix": "9-662_v1_7",
            "start": 612,
            "end": 782,
            "label": {}
        },
        {
            "ix": "9-662_v1_7@6",
            "content": "However, estimated average survival following MRT diagnosis has been reported to be six months <REF-10> .",
            "ntype": "s",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            },
            "src_ix": "9-662_v1_7",
            "start": 784,
            "end": 888,
            "label": {}
        },
        {
            "ix": "9-662_v1_8@0",
            "content": "Table 1.",
            "ntype": "s",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            },
            "src_ix": "9-662_v1_8",
            "start": 0,
            "end": 7,
            "label": {}
        },
        {
            "ix": "9-662_v1_10@0",
            "content": "ES is now categorized into two subgroups: distal and proximal.",
            "ntype": "s",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            },
            "src_ix": "9-662_v1_10",
            "start": 0,
            "end": 61,
            "label": {}
        },
        {
            "ix": "9-662_v1_10@1",
            "content": "Conventional or distal-type ES tends to be histologically similar squamous cells.",
            "ntype": "s",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            },
            "src_ix": "9-662_v1_10",
            "start": 63,
            "end": 143,
            "label": {}
        },
        {
            "ix": "9-662_v1_10@2",
            "content": "Also, distal-type ES immunohistochemical (IHC) profiles can be diverse.",
            "ntype": "s",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            },
            "src_ix": "9-662_v1_10",
            "start": 145,
            "end": 215,
            "label": {}
        },
        {
            "ix": "9-662_v1_10@3",
            "content": "Proximal-type ES is thought to be the more aggressive variant, and has an affinity for the proximal limbs of young adults.",
            "ntype": "s",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            },
            "src_ix": "9-662_v1_10",
            "start": 217,
            "end": 338,
            "label": {}
        },
        {
            "ix": "9-662_v1_10@4",
            "content": "Microscopically, sheets of large rhabdoid tumor cells are predominantly observed <REF-50> .",
            "ntype": "s",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            },
            "src_ix": "9-662_v1_10",
            "start": 340,
            "end": 430,
            "label": {}
        },
        {
            "ix": "9-662_v1_10@5",
            "content": "Based on more recent clinicopathologic and IHC data, many tumors that were previously diagnosed as a MRT are now classified as proximal ES <REF-51> .",
            "ntype": "s",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            },
            "src_ix": "9-662_v1_10",
            "start": 432,
            "end": 580,
            "label": {}
        },
        {
            "ix": "9-662_v1_11@0",
            "content": "In addition to ES, atypical teratoid/rhabdoid tumor, renal medullary carcinoma, and pediatric chordoma are rare sarcomas that result from the complete loss of SMARCB1/INI1 expression ( Table 1 ).",
            "ntype": "s",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            },
            "src_ix": "9-662_v1_11",
            "start": 0,
            "end": 194,
            "label": {}
        },
        {
            "ix": "9-662_v1_11@1",
            "content": "They predominantly occur in pediatric or young adult patients.",
            "ntype": "s",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            },
            "src_ix": "9-662_v1_11",
            "start": 196,
            "end": 257,
            "label": {}
        },
        {
            "ix": "9-662_v1_11@2",
            "content": "Collectively, these neoplasms typically develop in the head/neck, CNS, thorax, kidneys, other visceral organs, retroperitoneum, trunk, and extremities <REF-12> , <REF-17> , <REF-19> , <REF-26> , <REF-52> .",
            "ntype": "s",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            },
            "src_ix": "9-662_v1_11",
            "start": 259,
            "end": 463,
            "label": {}
        },
        {
            "ix": "9-662_v1_11@3",
            "content": "Exceedingly rare SMARCB1/INI1-deficient tumors that occur more commonly in adults include synovial sarcomas, epithelioid malignant peripheral nerve sheath tumor, myoepithelial carcinoma, extraskeletal myxoid chondrosarcoma, chordoma, schwannomatosis, gastrointestinal stromal tumors (GIST), and ossifying fibromyxoid tumor ( Table 1 ).",
            "ntype": "s",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            },
            "src_ix": "9-662_v1_11",
            "start": 465,
            "end": 799,
            "label": {}
        },
        {
            "ix": "9-662_v1_11@4",
            "content": "On light microscopy, these sarcomatous neoplasms exist on a morphological spectrum.",
            "ntype": "s",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            },
            "src_ix": "9-662_v1_11",
            "start": 801,
            "end": 883,
            "label": {}
        },
        {
            "ix": "9-662_v1_11@5",
            "content": "Tissue specimens are often composed of epithelioid or rhabdoid cells <REF-53> .",
            "ntype": "s",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            },
            "src_ix": "9-662_v1_11",
            "start": 885,
            "end": 963,
            "label": {}
        },
        {
            "ix": "9-662_v1_11@6",
            "content": "However, other morphologic patterns have been described <REF-50> .",
            "ntype": "s",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            },
            "src_ix": "9-662_v1_11",
            "start": 965,
            "end": 1030,
            "label": {}
        },
        {
            "ix": "9-662_v1_11@7",
            "content": "Thus, the diagnosis of SMARCB1/INI1-deficient tumors can be difficult based on their polyphenotypic variation <REF-4> .",
            "ntype": "s",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            },
            "src_ix": "9-662_v1_11",
            "start": 1032,
            "end": 1150,
            "label": {}
        },
        {
            "ix": "9-662_v1_11@8",
            "content": "SMARCB1/INI1 immunostaining can be used to confirm the diagnosis of an epithelioid or rhabdoid sarcoma because loss of SMARCB1/INI1 expression is rarely observed in other tumor types <REF-54> , <REF-55> .",
            "ntype": "s",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            },
            "src_ix": "9-662_v1_11",
            "start": 1152,
            "end": 1355,
            "label": {}
        },
        {
            "ix": "9-662_v1_11@9",
            "content": "Thus, in the absence of this genetic alteration, other malignant soft tissue tumors with epithelioid-like morphologies can be more confidently ruled out, such as melanoma, rhabdomyosarcoma, and undifferentiated carcinoma.",
            "ntype": "s",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            },
            "src_ix": "9-662_v1_11",
            "start": 1357,
            "end": 1577,
            "label": {}
        },
        {
            "ix": "9-662_v1_12@0",
            "content": "Aside from SMARCB1/INI1-deficient tumors sharing an aberration in the same gene, the relationship between these malignancies remains unclear.",
            "ntype": "s",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            },
            "src_ix": "9-662_v1_12",
            "start": 0,
            "end": 140,
            "label": {}
        },
        {
            "ix": "9-662_v1_12@1",
            "content": "Following diagnosis in any age or organ, nearly all SMARCB1/INI1-deficient malignancies characteristically follow an aggressive clinical pattern and prognosis if often poor ( Table 1 ).",
            "ntype": "s",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            },
            "src_ix": "9-662_v1_12",
            "start": 142,
            "end": 326,
            "label": {}
        },
        {
            "ix": "9-662_v1_12@2",
            "content": "Survival rates are often reportedly low, but they may not be accurate given low rates of incidence, and considerations for newer treatments.",
            "ntype": "s",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            },
            "src_ix": "9-662_v1_12",
            "start": 328,
            "end": 467,
            "label": {}
        },
        {
            "ix": "9-662_v1_12@3",
            "content": "Also, survival can be highly dependent on surgical intervention and completeness of tumor resection, especially for chordomas.",
            "ntype": "s",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            },
            "src_ix": "9-662_v1_12",
            "start": 469,
            "end": 594,
            "label": {}
        },
        {
            "ix": "9-662_v1_12@4",
            "content": "GIST are the most common sarcomas of the gastrointestinal (GI) tract.",
            "ntype": "s",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            },
            "src_ix": "9-662_v1_12",
            "start": 596,
            "end": 664,
            "label": {}
        },
        {
            "ix": "9-662_v1_12@5",
            "content": "They commonly develop in the sixth decade of life and have no gender predominance <REF-35> .",
            "ntype": "s",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            },
            "src_ix": "9-662_v1_12",
            "start": 666,
            "end": 757,
            "label": {}
        },
        {
            "ix": "9-662_v1_12@6",
            "content": "Following the diagnosis of a GIST, survival rates are highly variable and depend on specific biologic characteristics of the tumor, the type of treatment, and the risk of post-treatment recurrence <REF-36> .",
            "ntype": "s",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            },
            "src_ix": "9-662_v1_12",
            "start": 759,
            "end": 965,
            "label": {}
        },
        {
            "ix": "9-662_v1_13@0",
            "content": "Challenges in retrospective data collection for adult cases of SMARCB1/INI-deficient tumors",
            "ntype": "s",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            },
            "src_ix": "9-662_v1_13",
            "start": 0,
            "end": 90,
            "label": {}
        },
        {
            "ix": "9-662_v1_14@0",
            "content": "Recently, the term \u201crhabdoid tumor\u201d has become synonymous with tumors that harbor loss of function mutations in the SMARCB1/INI1 gene <REF-56> .",
            "ntype": "s",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            },
            "src_ix": "9-662_v1_14",
            "start": 0,
            "end": 143,
            "label": {}
        },
        {
            "ix": "9-662_v1_14@1",
            "content": "We reviewed the literature and found a paucity of cases reporting SMARCB1/INI1 genetic aberrations in adult patients with sarcomas.",
            "ntype": "s",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            },
            "src_ix": "9-662_v1_14",
            "start": 145,
            "end": 275,
            "label": {}
        },
        {
            "ix": "9-662_v1_14@2",
            "content": "A total of 450 cases of rare sarcomas were found to be described in single case reports, case series, or systematic reviews published between the years 2000 \u2013 2020 ( Table 2 ) <REF-57> \u2013 <REF-92> .",
            "ntype": "s",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            },
            "src_ix": "9-662_v1_14",
            "start": 277,
            "end": 473,
            "label": {}
        },
        {
            "ix": "9-662_v1_14@3",
            "content": "This number is likely far lower than the actual accounts of reported sarcoma cases in the literature.",
            "ntype": "s",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            },
            "src_ix": "9-662_v1_14",
            "start": 475,
            "end": 575,
            "label": {}
        },
        {
            "ix": "9-662_v1_14@4",
            "content": "However, reports were excluded if it was apparent the case did not meet our inclusion criteria based on the publicly-available title or abstract information.",
            "ntype": "s",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            },
            "src_ix": "9-662_v1_14",
            "start": 577,
            "end": 733,
            "label": {}
        },
        {
            "ix": "9-662_v1_14@5",
            "content": "Despite the SMARCB1/INI1 gene being discovered in the mid-1990\u2019s, the majority of previous reports were excluded for not mentioning the tumor\u2019s SMARCB1/INI1-deficiency status.",
            "ntype": "s",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            },
            "src_ix": "9-662_v1_14",
            "start": 735,
            "end": 909,
            "label": {}
        },
        {
            "ix": "9-662_v1_14@6",
            "content": "Also, tumor occurrence in the pediatric patient population accounted for multiple exclusions.",
            "ntype": "s",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            },
            "src_ix": "9-662_v1_14",
            "start": 911,
            "end": 1003,
            "label": {}
        },
        {
            "ix": "9-662_v1_15@0",
            "content": "Table 2.",
            "ntype": "s",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            },
            "src_ix": "9-662_v1_15",
            "start": 0,
            "end": 7,
            "label": {}
        },
        {
            "ix": "9-662_v1_17@0",
            "content": "We located 25 cases of adult SMARCB1/INI1-deficient sarcomas that were described in 18 reports ( Table 3 ) <REF-42> , <REF-50> , <REF-93> \u2013 <REF-108> .",
            "ntype": "s",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            },
            "src_ix": "9-662_v1_17",
            "start": 0,
            "end": 150,
            "label": {}
        },
        {
            "ix": "9-662_v1_17@1",
            "content": "Median age at the time of diagnosis was 36 years old.",
            "ntype": "s",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            },
            "src_ix": "9-662_v1_17",
            "start": 152,
            "end": 204,
            "label": {}
        },
        {
            "ix": "9-662_v1_17@2",
            "content": "A male predominance was mildly observed (14 cases, 56%), which is consistent with other larger reviews.",
            "ntype": "s",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            },
            "src_ix": "9-662_v1_17",
            "start": 206,
            "end": 308,
            "label": {}
        },
        {
            "ix": "9-662_v1_17@3",
            "content": "Presentation in the head and neck (e.g. brain, eye, nose, and scalp) occurred more frequently (6 cases, 24%).",
            "ntype": "s",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            },
            "src_ix": "9-662_v1_17",
            "start": 310,
            "end": 418,
            "label": {}
        },
        {
            "ix": "9-662_v1_17@4",
            "content": "No descriptive data analysis was performed to determine if our observations were significant.",
            "ntype": "s",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            },
            "src_ix": "9-662_v1_17",
            "start": 420,
            "end": 512,
            "label": {}
        },
        {
            "ix": "9-662_v1_17@5",
            "content": "The majority of reports were originally described as proximal epithelioid sarcoma, but overall these remained a morphologically diverse group of cases that also included rhabdoid and mixed phenotypes.",
            "ntype": "s",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            },
            "src_ix": "9-662_v1_17",
            "start": 514,
            "end": 713,
            "label": {}
        },
        {
            "ix": "9-662_v1_18@0",
            "content": "Table 3.",
            "ntype": "s",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            },
            "src_ix": "9-662_v1_18",
            "start": 0,
            "end": 7,
            "label": {}
        },
        {
            "ix": "9-662_v1_20@0",
            "content": "Treatment",
            "ntype": "s",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            },
            "src_ix": "9-662_v1_20",
            "start": 0,
            "end": 8,
            "label": {}
        },
        {
            "ix": "9-662_v1_21@0",
            "content": "Prior to, and still after, the discovery that SMARCB1/INI1-deficient tumors contribute to the large majority of soft tissue sarcomas, systemic cytotoxic agents have been used to treat this diverse group of neoplasms.",
            "ntype": "s",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            },
            "src_ix": "9-662_v1_21",
            "start": 0,
            "end": 215,
            "label": {}
        },
        {
            "ix": "9-662_v1_21@1",
            "content": "Doxorubicin and ifosfamide have remained the mainstay of first-line treatment for advanced disease for the last few decades.",
            "ntype": "s",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            },
            "src_ix": "9-662_v1_21",
            "start": 217,
            "end": 340,
            "label": {}
        },
        {
            "ix": "9-662_v1_21@2",
            "content": "Currently, the most widely used regimen for soft tissue sarcomas is termed AIM, which includes doxorubicin plus ifosfamide and mesna <REF-109> \u2013 <REF-111> .",
            "ntype": "s",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            },
            "src_ix": "9-662_v1_21",
            "start": 342,
            "end": 497,
            "label": {}
        },
        {
            "ix": "9-662_v1_21@3",
            "content": "Therapies such as these, and other cytotoxic agents, exhibit intermediate to improved anti-cancer activity, and prolong survival in metastatic soft tissue sarcoma ( Table 4 ).",
            "ntype": "s",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            },
            "src_ix": "9-662_v1_21",
            "start": 499,
            "end": 673,
            "label": {}
        },
        {
            "ix": "9-662_v1_21@4",
            "content": "However, refractory or progressive disease can occur.",
            "ntype": "s",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            },
            "src_ix": "9-662_v1_21",
            "start": 675,
            "end": 727,
            "label": {}
        },
        {
            "ix": "9-662_v1_21@5",
            "content": "With the hopes of improving outcomes in patients who develop aggressive sarcomas, multiple new therapies are being introduced.",
            "ntype": "s",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            },
            "src_ix": "9-662_v1_21",
            "start": 729,
            "end": 854,
            "label": {}
        },
        {
            "ix": "9-662_v1_21@6",
            "content": "Olaratumab, a monoclonal antibody that targets platelet-derived growth factor alpha and beta (PDGFRA/B), has been approved for first-line therapy in combination with doxorubicin due to improved progression and overall survival in sarcoma patients <REF-112> .",
            "ntype": "s",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            },
            "src_ix": "9-662_v1_21",
            "start": 856,
            "end": 1113,
            "label": {}
        },
        {
            "ix": "9-662_v1_21@7",
            "content": "The use of tyrosine kinase-inhibitors (TKIs) has transformed the treatment of advanced GIST.",
            "ntype": "s",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            },
            "src_ix": "9-662_v1_21",
            "start": 1115,
            "end": 1206,
            "label": {}
        },
        {
            "ix": "9-662_v1_21@8",
            "content": "Imatinib, a TKI, as monotherapy is now approved for upfront treatment of metastatic GIST due to improved side effect profiles and outcomes in these patients <REF-113> \u2013 <REF-115> .",
            "ntype": "s",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            },
            "src_ix": "9-662_v1_21",
            "start": 1208,
            "end": 1387,
            "label": {}
        },
        {
            "ix": "9-662_v1_21@9",
            "content": "Given its mechanism of action, imatinib is also approved for first-line treatment of the fibrosarcomatous variant of dermatofibrosarcoma protuberans <REF-116> , <REF-117> .",
            "ntype": "s",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            },
            "src_ix": "9-662_v1_21",
            "start": 1389,
            "end": 1560,
            "label": {}
        },
        {
            "ix": "9-662_v1_22@0",
            "content": "Table 4.",
            "ntype": "s",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            },
            "src_ix": "9-662_v1_22",
            "start": 0,
            "end": 7,
            "label": {}
        },
        {
            "ix": "9-662_v1_24@0",
            "content": "Additional TKIs have recently been introduced, with clinical trial data showing promise for their use in sarcomas.",
            "ntype": "s",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            },
            "src_ix": "9-662_v1_24",
            "start": 0,
            "end": 113,
            "label": {}
        },
        {
            "ix": "9-662_v1_24@1",
            "content": "Sunitinib and regorafenib significantly improve overall survival in imatinib-resistant GIST patients <REF-118> .",
            "ntype": "s",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            },
            "src_ix": "9-662_v1_24",
            "start": 115,
            "end": 226,
            "label": {}
        },
        {
            "ix": "9-662_v1_24@2",
            "content": "Pazopanib, a TKI that targets angiogenesis by inhibiting vascular endothelial growth factor receptor, PDGFRA/B, and KIT, has been shown to improve progression free survival in certain histologic types of sarcoma.",
            "ntype": "s",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            },
            "src_ix": "9-662_v1_24",
            "start": 228,
            "end": 439,
            "label": {}
        },
        {
            "ix": "9-662_v1_24@3",
            "content": "This led to its approval for advanced, refractory non-lipomatous sarcoma <REF-119> , <REF-120> .",
            "ntype": "s",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            },
            "src_ix": "9-662_v1_24",
            "start": 441,
            "end": 536,
            "label": {}
        },
        {
            "ix": "9-662_v1_24@4",
            "content": "Alveolar sarcomas appear to respond well to anti-angiogenetic sorafenib and cediranib <REF-121> , <REF-122> .",
            "ntype": "s",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            },
            "src_ix": "9-662_v1_24",
            "start": 538,
            "end": 646,
            "label": {}
        },
        {
            "ix": "9-662_v1_24@5",
            "content": "In phase II studies tivozanib, which mechanism of action mimics pazopanib, exhibits promising anti-cancer activity in metastatic or nonresectable soft tissue sarcomas <REF-123> .",
            "ntype": "s",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            },
            "src_ix": "9-662_v1_24",
            "start": 648,
            "end": 825,
            "label": {}
        },
        {
            "ix": "9-662_v1_25@0",
            "content": "Recently, much work studying the complex mechanisms involved in sarcoma tumorigenesis has revealed the potential for numerous new drug targets.",
            "ntype": "s",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            },
            "src_ix": "9-662_v1_25",
            "start": 0,
            "end": 142,
            "label": {}
        },
        {
            "ix": "9-662_v1_25@1",
            "content": "Targeting mTOR by serine/threonine kinase inhibition has been widely studied.",
            "ntype": "s",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            },
            "src_ix": "9-662_v1_25",
            "start": 144,
            "end": 220,
            "label": {}
        },
        {
            "ix": "9-662_v1_25@2",
            "content": "However, thus far either only equivocal or minor benefits have been shown with the administration of these agents <REF-124> .",
            "ntype": "s",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            },
            "src_ix": "9-662_v1_25",
            "start": 222,
            "end": 346,
            "label": {}
        },
        {
            "ix": "9-662_v1_25@3",
            "content": "In contrast, phase II trial data is reassuring for the future use of palbociclib, a cyclin-dependent kinase 4 and 6 inhibitor approved in breast cancer, for liposarcoma <REF-125> , <REF-126> .",
            "ntype": "s",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            },
            "src_ix": "9-662_v1_25",
            "start": 348,
            "end": 539,
            "label": {}
        },
        {
            "ix": "9-662_v1_26@0",
            "content": "Preliminary data from pre-clinical and phase I/II trials is encouraging for small molecule inhibitors, such as with MDM2-antagonists, histone deacetylase inhibitors, and histone methylation inhibitors <REF-124> .",
            "ntype": "s",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            },
            "src_ix": "9-662_v1_26",
            "start": 0,
            "end": 211,
            "label": {}
        },
        {
            "ix": "9-662_v1_26@1",
            "content": "A possible breakthrough in small molecular inhibition is represented by the recent discovery of histone-lysine N-methyltransferase EZH2 upregulation in SMARCB1/INI1-deficient tumors <REF-127> .",
            "ntype": "s",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            },
            "src_ix": "9-662_v1_26",
            "start": 213,
            "end": 405,
            "label": {}
        },
        {
            "ix": "9-662_v1_26@2",
            "content": "Given the defining characteristic of SMARCB1/INI1 deficiency in the nearly all soft tissue sarcomas, tazemetostat has emerged as a highly intriguing compound for its direct inhibition of histone-lysine N-methyltransferase EZH2 <REF-138> , <REF-139> .",
            "ntype": "s",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            },
            "src_ix": "9-662_v1_26",
            "start": 407,
            "end": 656,
            "label": {}
        },
        {
            "ix": "9-662_v1_26@3",
            "content": "Another new agent that hopes to improve outcomes for patients with these rare and aggressive SMARCB1/INI1-deficient rhabdoid sarcomas comes from the proteasome inhibitor drug class.",
            "ntype": "s",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            },
            "src_ix": "9-662_v1_26",
            "start": 658,
            "end": 838,
            "label": {}
        },
        {
            "ix": "9-662_v1_26@4",
            "content": "Ixazomib selectively targets proteasomes involved in protein anabolism and cellular apoptosis, whose activity is directly enhanced by the transcription factor MYC in SMARCB1/INI1 -deficient states.",
            "ntype": "s",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            },
            "src_ix": "9-662_v1_26",
            "start": 840,
            "end": 1036,
            "label": {}
        },
        {
            "ix": "9-662_v1_26@5",
            "content": "Currently, ixazomib plus gemcitabine and doxorubicin is being studied in the phase II trial setting for renal medullary carcinoma <REF-140> , <REF-141> .",
            "ntype": "s",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            },
            "src_ix": "9-662_v1_26",
            "start": 1038,
            "end": 1190,
            "label": {}
        },
        {
            "ix": "9-662_v1_27@0",
            "content": "Data availability",
            "ntype": "s",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            },
            "src_ix": "9-662_v1_27",
            "start": 0,
            "end": 16,
            "label": {}
        },
        {
            "ix": "9-662_v1_28@0",
            "content": "Underlying data",
            "ntype": "s",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            },
            "src_ix": "9-662_v1_28",
            "start": 0,
            "end": 14,
            "label": {}
        },
        {
            "ix": "9-662_v1_29@0",
            "content": "No data are associated with this article.",
            "ntype": "s",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            },
            "src_ix": "9-662_v1_29",
            "start": 0,
            "end": 40,
            "label": {}
        },
        {
            "ix": "9-662_v1_30@0",
            "content": "<REF-1> Abrams E Neigeborn L Carlson M : Molecular analysis of SNF2 and SNF5, genes required for expression of glucose-repressible genes in Saccharomyces cerevisiae. Mol Cell Biol. 1986 ; 6 ( 11 ): 3643 \u2013 3651 . 3540598 10.1128/mcb.6.11.3643 367125",
            "ntype": "s",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            },
            "src_ix": "9-662_v1_30",
            "start": 0,
            "end": 247,
            "label": {}
        },
        {
            "ix": "9-662_v1_31@0",
            "content": "<REF-2> Kalpana GV Marmon S Wang W : Binding and stimulation of HIV-1 integrase by a human homolog of yeast transcription factor SNF5. Science. 1994 ; 266 ( 5193 ): 2002 \u2013 2006 . 7801128 10.1126/science.7801128",
            "ntype": "s",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            },
            "src_ix": "9-662_v1_31",
            "start": 0,
            "end": 209,
            "label": {}
        },
        {
            "ix": "9-662_v1_32@0",
            "content": "<REF-3> Muchardt C Sardet C Bourachot B : A human protein with homology to Saccharomyces cerevisiae SNF5 interacts with the potential helicase hbrm. Nucleic Acids Res. 1995 ; 23 ( 7 ): 1127 \u2013 1132 . 7739891 10.1093/nar/23.7.1127 306820",
            "ntype": "s",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            },
            "src_ix": "9-662_v1_32",
            "start": 0,
            "end": 234,
            "label": {}
        },
        {
            "ix": "9-662_v1_33@0",
            "content": "<REF-4> Hollmann TJ Hornick JL : INI1-deficient tumors: diagnostic features and molecular genetics. Am J Surg Pathol. 2011 ; 35 ( 10 ): e47 \u2013 63 . 21934399 10.1097/PAS.0b013e31822b325b",
            "ntype": "s",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            },
            "src_ix": "9-662_v1_33",
            "start": 0,
            "end": 183,
            "label": {}
        },
        {
            "ix": "9-662_v1_34@0",
            "content": "<REF-5> Guidi CJ Sands AT Zambrowicz BP : Disruption of Ini1 leads to peri-implantation lethality and tumorigenesis in mice. Mol Cell Biol. 2001 ; 21 ( 10 ): 3598 \u2013 3603 . 11313485 10.1128/MCB.21.10.3598-3603.2001 100281",
            "ntype": "s",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            },
            "src_ix": "9-662_v1_34",
            "start": 0,
            "end": 219,
            "label": {}
        },
        {
            "ix": "9-662_v1_35@0",
            "content": "<REF-6> Roberts CW Orkin SH : The SWI/SNF complex--chromatin and cancer. Nat Rev Cancer. 2004 ; 4 ( 2 ): 133 \u2013 142 . 14964309 10.1038/nrc1273",
            "ntype": "s",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            },
            "src_ix": "9-662_v1_35",
            "start": 0,
            "end": 140,
            "label": {}
        },
        {
            "ix": "9-662_v1_36@0",
            "content": "<REF-8> Roberts CW Leroux MM Fleming MD : Highly penetrant, rapid tumorigenesis through conditional inversion of the tumor suppressor gene Snf5. Cancer Cell. 2002 ; 2 ( 5 ): 415 \u2013 425 . 12450796 10.1016/s1535-6108(02)00185-x",
            "ntype": "s",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            },
            "src_ix": "9-662_v1_36",
            "start": 0,
            "end": 223,
            "label": {}
        },
        {
            "ix": "9-662_v1_37@0",
            "content": "<REF-9> Kohashi K Oda Y : Oncogenic roles of SMARCB1/INI1 and its deficient tumors. Cancer Sci. 2017 ; 108 ( 4 ): 547 \u2013 552 . 28109176 10.1111/cas.13173 5406539",
            "ntype": "s",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            },
            "src_ix": "9-662_v1_37",
            "start": 0,
            "end": 159,
            "label": {}
        },
        {
            "ix": "9-662_v1_38@0",
            "content": "<REF-10> Ferrari A Sultan I Huang TT : Soft tissue sarcoma across the age spectrum: a population-based study from the Surveillance Epidemiology and End Results database. Pediatr Blood Cancer.. 2011 ; 57 ( 6 ): 943 \u2013 9 . 21793180 10.1002/pbc.23252 4261144",
            "ntype": "s",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            },
            "src_ix": "9-662_v1_38",
            "start": 0,
            "end": 253,
            "label": {}
        },
        {
            "ix": "9-662_v1_39@0",
            "content": "<REF-12> Shonka NA Armstrong TS Prabhu SS : Atypical teratoid/rhabdoid tumors in adults: a case report and treatment-focused review. J Clin Med Res. 2011 ; 3 ( 2 ): 85 \u2013 92 . 21811535 10.4021/jocmr535w 3140928",
            "ntype": "s",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            },
            "src_ix": "9-662_v1_39",
            "start": 0,
            "end": 208,
            "label": {}
        },
        {
            "ix": "9-662_v1_40@0",
            "content": "<REF-13> Doyle LA : Malignant rhabdoid tumor: Pathology of Human Disease. Academic press; 2014 .",
            "ntype": "s",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            },
            "src_ix": "9-662_v1_40",
            "start": 0,
            "end": 95,
            "label": {}
        },
        {
            "ix": "9-662_v1_41@0",
            "content": "<REF-14> Horazdovsky R Manivel JC Cheng EY : Successful salvage and long-term survival after recurrent malignant rhabdoid tumor. Sarcoma. 2007 ; 2007 : 53549 . 17671630 10.1155/2007/53549 1920592",
            "ntype": "s",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            },
            "src_ix": "9-662_v1_41",
            "start": 0,
            "end": 194,
            "label": {}
        },
        {
            "ix": "9-662_v1_42@0",
            "content": "<REF-17> Needs T Fillman EP : Cancer, Epithelioid Sarcoma. StatPearls. Treasure Island (FL): StatPearls. 2020 . 30422506",
            "ntype": "s",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            },
            "src_ix": "9-662_v1_42",
            "start": 0,
            "end": 119,
            "label": {}
        },
        {
            "ix": "9-662_v1_43@0",
            "content": "<REF-19> Shetty A Matrana MR : Renal medullary carcinoma: a case report and brief review of the literature. Ochsner J. 2014 ; 14 ( 2 ): 270 \u2013 5 . 24940141 4052598",
            "ntype": "s",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            },
            "src_ix": "9-662_v1_43",
            "start": 0,
            "end": 161,
            "label": {}
        },
        {
            "ix": "9-662_v1_44@0",
            "content": "<REF-26> Beccaria K Sainte-Rose C Zerah M : Paediatric Chordomas. Orphanet J Rare Dis. 2015 ; 10 : 116 . 26391590 10.1186/s13023-015-0340-8 4578760",
            "ntype": "s",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            },
            "src_ix": "9-662_v1_44",
            "start": 0,
            "end": 146,
            "label": {}
        },
        {
            "ix": "9-662_v1_45@0",
            "content": "<REF-35> Morgan J Raut CP Duensing A : Epidemiology, classification, clinical presentation, prognostic features, and diagnostic work-up of gastrointestinal stromal tumors (GIST). UpToDate. 2019 . Reference Source",
            "ntype": "s",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            },
            "src_ix": "9-662_v1_45",
            "start": 0,
            "end": 211,
            "label": {}
        },
        {
            "ix": "9-662_v1_46@0",
            "content": "<REF-36> DeMatteo RP Lewis JJ Leung D : Two hundred gastrointestinal stromal tumors: recurrence patterns and prognostic factors for survival. Ann Surg. 2000 ; 231 ( 1 ): 51 \u2013 58 . 10636102 10.1097/00000658-200001000-00008 1420965",
            "ntype": "s",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            },
            "src_ix": "9-662_v1_46",
            "start": 0,
            "end": 228,
            "label": {}
        },
        {
            "ix": "9-662_v1_47@0",
            "content": "<REF-41> Pawel BR : SMARCB1-deficient Tumors of Childhood: A Practical Guide. Pediatr Dev Pathol. 2018 ; 21 ( 1 ): 6 \u2013 28 . 29280680 10.1177/1093526617749671",
            "ntype": "s",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            },
            "src_ix": "9-662_v1_47",
            "start": 0,
            "end": 156,
            "label": {}
        },
        {
            "ix": "9-662_v1_48@0",
            "content": "<REF-42> Parker NA Al-Obaidi A Lalich D : SMARCB1/INI1-Deficient Extrarenal Rhabdoid Tumor: A Case Report of a Rare and Aggressive Soft Tissue Sarcoma. Cureus. 2020 ; 12 ( 5 ): e8273 . 32467817 10.7759/cureus.8273 7250519",
            "ntype": "s",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            },
            "src_ix": "9-662_v1_48",
            "start": 0,
            "end": 220,
            "label": {}
        },
        {
            "ix": "9-662_v1_49@0",
            "content": "<REF-49> Zhao G Na R Yang Y : Pure malignant rhabdoid tumor of the left kidney in an adult: A case report and review of the literature. Oncol Lett. 2013 ; 5 ( 5 ): 1481 \u2013 1484 . 23761028 10.3892/ol.2013.1207 3678854",
            "ntype": "s",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            },
            "src_ix": "9-662_v1_49",
            "start": 0,
            "end": 214,
            "label": {}
        },
        {
            "ix": "9-662_v1_50@0",
            "content": "<REF-50> Modena P Lualdi E Facchinetti F : SMARCB1/INI1 tumor suppressor gene is frequently inactivated in epithelioid sarcomas. Cancer Res.. 2005 ; 65 ( 10 ): 4012 \u2013 9 . 15899790 10.1158/0008-5472.CAN-04-3050",
            "ntype": "s",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            },
            "src_ix": "9-662_v1_50",
            "start": 0,
            "end": 208,
            "label": {}
        },
        {
            "ix": "9-662_v1_51@0",
            "content": "<REF-51> Margol AS Judkins AR : Pathology and diagnosis of SMARCB1-deficient tumors. Cancer Genet. 2014 ; 207 ( 9 ): 358 \u2013 64 . 25246033 10.1016/j.cancergen.2014.07.004",
            "ntype": "s",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            },
            "src_ix": "9-662_v1_51",
            "start": 0,
            "end": 167,
            "label": {}
        },
        {
            "ix": "9-662_v1_52@0",
            "content": "<REF-52> Ng WK Toe BP Lau HY : Malignant Rhabdoid Tumor of the Mediastinum: A Case Report and Literature Review. J Clin Imaging Sci. 2019 ; 9 : 7 . 31448158 10.25259/JCIS-9-7 6702892",
            "ntype": "s",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            },
            "src_ix": "9-662_v1_52",
            "start": 0,
            "end": 181,
            "label": {}
        },
        {
            "ix": "9-662_v1_53@0",
            "content": "<REF-53> Gupta RK Batra VV Das MC : Malignant extra-renal rhabdoid tumor with unusual presentation: A report of two cases. J Cancer Res Ther. 2015 ; 11 ( 4 ): 963 \u2013 6 . 26881557 10.4103/0973-1482.163668",
            "ntype": "s",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            },
            "src_ix": "9-662_v1_53",
            "start": 0,
            "end": 201,
            "label": {}
        },
        {
            "ix": "9-662_v1_54@0",
            "content": "<REF-54> Hoot AC Russo P Judkins AR : Immunohistochemical analysis of hSNF5/INI1 distinguishes renal and extra-renal malignant rhabdoid tumors from other pediatric soft tissue tumors. Am J Surg Pathol.. 2004 ; 28 ( 11 ): 1485 \u2013 91 . 15489652 10.1097/01.pas.0000141390.14548.34",
            "ntype": "s",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            },
            "src_ix": "9-662_v1_54",
            "start": 0,
            "end": 275,
            "label": {}
        },
        {
            "ix": "9-662_v1_55@0",
            "content": "<REF-55> Chbani L Guillou L Terrier P : Epithelioid sarcoma: a clinicopathologic and immunohistochemical analysis of 106 cases from the French sarcoma group. Am J Clin Pathol. 2009 ; 131 ( 2 ): 222 \u2013 227 . 19141382 10.1309/AJCPU98ABIPVJAIV",
            "ntype": "s",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            },
            "src_ix": "9-662_v1_55",
            "start": 0,
            "end": 238,
            "label": {}
        },
        {
            "ix": "9-662_v1_56@0",
            "content": "<REF-56> Kohashi K Tanaka Y Kishimoto H : Reclassification of rhabdoid tumor and pediatric undifferentiated/unclassified sarcoma with complete loss of SMARCB1/INI1 protein expression: three subtypes of rhabdoid tumor according to their histological features. Mod Pathol. 2016 ; 29 ( 10 ): 1232 \u2013 1242 . 10.1038/modpathol.2016.106",
            "ntype": "s",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            },
            "src_ix": "9-662_v1_56",
            "start": 0,
            "end": 328,
            "label": {}
        },
        {
            "ix": "9-662_v1_57@0",
            "content": "<REF-57> Zhang XW Deng YJ Zhou L : Epithelioid sarcoma of the scalp: a case report and literature review. Int J Clin Exp Pathol. 2019 ; 12 ( 10 ): 3908 \u2013 3914 . 31933781 6949740",
            "ntype": "s",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            },
            "src_ix": "9-662_v1_57",
            "start": 0,
            "end": 176,
            "label": {}
        },
        {
            "ix": "9-662_v1_58@0",
            "content": "<REF-92> Spillane AJ Thomas JM Fisher C : Epithelioid sarcoma: the clinicopathological complexities of this rare soft tissue sarcoma. Ann Surg Oncol. 2000 ; 7 ( 3 ): 218 \u2013 225 . 10791853 10.1007/BF02523657",
            "ntype": "s",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            },
            "src_ix": "9-662_v1_58",
            "start": 0,
            "end": 204,
            "label": {}
        },
        {
            "ix": "9-662_v1_59@0",
            "content": "<REF-93> Ahmad Z Stanazai Q Wright S : Primary pleural epithelioid sarcoma of the proximal type: a diagnostic and therapeutic challenge. Transl Lung Cancer Res. 2019 ; 8 ( 5 ): 700 \u2013 705 . 31737506 10.21037/tlcr.2019.09.16 6835107",
            "ntype": "s",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            },
            "src_ix": "9-662_v1_59",
            "start": 0,
            "end": 229,
            "label": {}
        },
        {
            "ix": "9-662_v1_60@0",
            "content": "<REF-108> Perry A Fuller CE Judkins AR : INI1 expression is retained in composite rhabdoid tumors, including rhabdoid meningiomas. Mod Pathol. 2005 ; 18 ( 7 ): 951 \u2013 958 . 15761491 10.1038/modpathol.3800375",
            "ntype": "s",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            },
            "src_ix": "9-662_v1_60",
            "start": 0,
            "end": 205,
            "label": {}
        },
        {
            "ix": "9-662_v1_61@0",
            "content": "<REF-109> Edmonson JH Ryan LM Blum RH : Randomized comparison of doxorubicin alone versus ifosfamide plus doxorubicin or mitomycin, doxorubicin, and cisplatin against advanced soft tissue sarcomas. J Clin Oncol. 1993 ; 11 ( 7 ): 1269 \u2013 75 . 8315424 10.1200/JCO.1993.11.7.1269",
            "ntype": "s",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            },
            "src_ix": "9-662_v1_61",
            "start": 0,
            "end": 274,
            "label": {}
        },
        {
            "ix": "9-662_v1_62@0",
            "content": "<REF-111> Worden FP Taylor JM Biermann JS : Randomized phase II evaluation of 6 g/m 2 of ifosfamide plus doxorubicin and granulocyte colony-stimulating factor (G-CSF) compared with 12 g/m 2 of ifosfamide plus doxorubicin and G-CSF in the treatment of poor-prognosis soft tissue sarcoma. J Clin Oncol. 2005 ; 23 ( 1 ): 105 \u2013 12 . 15625365 10.1200/JCO.2005.05.108",
            "ntype": "s",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            },
            "src_ix": "9-662_v1_62",
            "start": 0,
            "end": 360,
            "label": {}
        },
        {
            "ix": "9-662_v1_63@0",
            "content": "<REF-112> Tap WD Jones RL Van Tine BA : Olaratumab and doxorubicin versus doxorubicin alone for treatment of soft-tissue sarcoma: an open-label phase 1b and randomised phase 2 trial . [published correction appears in Lancet. 2016 Jul 30; 388(10043):464]. Lancet. 2016 ; 388 ( 10043 ): 488 \u2013 497 . 27291997 10.1016/S0140-6736(16)30587-6 5647653",
            "ntype": "s",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            },
            "src_ix": "9-662_v1_63",
            "start": 0,
            "end": 342,
            "label": {}
        },
        {
            "ix": "9-662_v1_64@0",
            "content": "<REF-113> van Oosterom AT Judson I Verweij J : Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumours: a phase I study. Lancet. 2001 ; 358 ( 9291 ): 1421 \u2013 1423 . 11705489 10.1016/s0140-6736(01)06535-7",
            "ntype": "s",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            },
            "src_ix": "9-662_v1_64",
            "start": 0,
            "end": 233,
            "label": {}
        },
        {
            "ix": "9-662_v1_65@0",
            "content": "<REF-115> Blanke CD Rankin C Demetri GD : Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033. J Clin Oncol. 2008 ; 26 ( 4 ): 626 \u2013 632 . 18235122 10.1200/JCO.2007.13.4452",
            "ntype": "s",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            },
            "src_ix": "9-662_v1_65",
            "start": 0,
            "end": 331,
            "label": {}
        },
        {
            "ix": "9-662_v1_66@0",
            "content": "<REF-116> Rutkowski P Van Glabbeke M Rankin CJ : Imatinib mesylate in advanced dermatofibrosarcoma protuberans: pooled analysis of two phase II clinical trials. J Clin Oncol. 2010 ; 28 ( 10 ): 1772 \u2013 1779 . 20194851 10.1200/JCO.2009.25.7899 3040044",
            "ntype": "s",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            },
            "src_ix": "9-662_v1_66",
            "start": 0,
            "end": 247,
            "label": {}
        },
        {
            "ix": "9-662_v1_67@0",
            "content": "<REF-117> Stacchiotti S Pantaleo MA Negri T : Efficacy and Biological Activity of Imatinib in Metastatic Dermatofibrosarcoma Protuberans (DFSP). Clin Cancer Res. 2016 ; 22 ( 4 ): 837 \u2013 846 . 26261104 10.1158/1078-0432.CCR-15-1243",
            "ntype": "s",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            },
            "src_ix": "9-662_v1_67",
            "start": 0,
            "end": 228,
            "label": {}
        },
        {
            "ix": "9-662_v1_68@0",
            "content": "<REF-118> Call JW Wang Y Montoya D : Survival in advanced GIST has improved over time and correlates with increased access to post-imatinib tyrosine kinase inhibitors: results from Life Raft Group Registry . [published correction appears in Clin Sarcoma Res. 2019 May 7;9:7]. Clin Sarcoma Res. 2019 ; 9 : 4 . 30984366 10.1186/s13569-019-0114-5 6446260",
            "ntype": "s",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            },
            "src_ix": "9-662_v1_68",
            "start": 0,
            "end": 350,
            "label": {}
        },
        {
            "ix": "9-662_v1_69@0",
            "content": "<REF-119> van der Graaf WTA Blay JY Chawla SP : Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet. 2012 ; 379 ( 9829 ): 1879 \u2013 86 . 22595799 10.1016/S0140-6736(12)60651-5",
            "ntype": "s",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            },
            "src_ix": "9-662_v1_69",
            "start": 0,
            "end": 244,
            "label": {}
        },
        {
            "ix": "9-662_v1_70@0",
            "content": "<REF-120> Sleijfer S Ray-Coquard I Papai Z : Pazopanib, a multikinase angiogenesis inhibitor, in patients with relapsed or refractory advanced soft tissue sarcoma: a phase II study from the European organisation for research and treatment of cancer-soft tissue and bone sarcoma group (EORTC study 62043). J Clin Oncol. 2009 ; 27 ( 19 ): 3126 \u2013 32 . 19451427 10.1200/JCO.2008.21.3223",
            "ntype": "s",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            },
            "src_ix": "9-662_v1_70",
            "start": 0,
            "end": 381,
            "label": {}
        },
        {
            "ix": "9-662_v1_71@0",
            "content": "<REF-121> Ray-Coquard I Italiano A Bompas E : Sorafenib for Patients With Advanced Angiosarcoma: A Phase II Trial From the French Sarcoma Group (GSF/GETO). Oncologist. 2012 ; 17 ( 2 ): 260 \u2013 266 . 22285963 10.1634/theoncologist.2011-0237 3286175",
            "ntype": "s",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            },
            "src_ix": "9-662_v1_71",
            "start": 0,
            "end": 244,
            "label": {}
        },
        {
            "ix": "9-662_v1_72@0",
            "content": "<REF-122> Kummar S Allen D Monks A : Cediranib for Metastatic Alveolar Soft Part Sarcoma. J Clin Oncol. 2013 ; 31 ( 18 ): 2296 \u2013 2302 . 23630200 10.1200/JCO.2012.47.4288 3677840",
            "ntype": "s",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            },
            "src_ix": "9-662_v1_72",
            "start": 0,
            "end": 176,
            "label": {}
        },
        {
            "ix": "9-662_v1_73@0",
            "content": "<REF-123> Agulnik M Costa RLB Milhem M : A Phase II Study of Tivozanib in Patients With Metastatic and Nonresectable Soft-Tissue Sarcomas. Ann Oncol. 2017 ; 28 ( 1 ): 121 \u2013 127 . 27771610 10.1093/annonc/mdw444 6246191",
            "ntype": "s",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            },
            "src_ix": "9-662_v1_73",
            "start": 0,
            "end": 216,
            "label": {}
        },
        {
            "ix": "9-662_v1_74@0",
            "content": "<REF-124> Frezza AM Stacchiotti S Gronchi A : Systemic Treatment in Advanced Soft Tissue Sarcoma: What Is Standard, What Is New. BMC Med. 2017 ; 15 ( 1 ): 109 . 28571564 10.1186/s12916-017-0872-y 5455204",
            "ntype": "s",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            },
            "src_ix": "9-662_v1_74",
            "start": 0,
            "end": 202,
            "label": {}
        },
        {
            "ix": "9-662_v1_75@0",
            "content": "<REF-125> Binh MB Sastre-Garau X Guillou L : MDM2 and CDK4 Immunostainings Are Useful Adjuncts in Diagnosing Well-Differentiated and Dedifferentiated Liposarcoma Subtypes: A Comparative Analysis of 559 Soft Tissue Neoplasms With Genetic Data. Am J Surg Pathol. 2005 ; 29 ( 10 ): 1340 \u2013 1347 . 16160477 10.1097/01.pas.0000170343.09562.39",
            "ntype": "s",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            },
            "src_ix": "9-662_v1_75",
            "start": 0,
            "end": 335,
            "label": {}
        },
        {
            "ix": "9-662_v1_76@0",
            "content": "<REF-126> Dickson MA Tap WD Keohan ML : Phase II trial of the CDK4 inhibitor PD0332991 in patients with advanced CDK4 -amplified well-differentiated or dedifferentiated liposarcoma. J Clin Oncol. 2013 ; 31 ( 16 ): 2024 \u2013 8 . 23569312 10.1200/JCO.2012.46.5476 3661937",
            "ntype": "s",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            },
            "src_ix": "9-662_v1_76",
            "start": 0,
            "end": 265,
            "label": {}
        },
        {
            "ix": "9-662_v1_77@0",
            "content": "<REF-127> Wilson BG Wang X Shen X : Epigenetic antagonism between polycomb and SWI/SNF complexes during oncogenic transformation . [published correction appears in Cancer Cell. 2011 Jan 18; 19(1): 153] Cancer Cell. 2010 ; 18 ( 4 ): 316 \u2013 28 . 20951942 10.1016/j.ccr.2010.09.006 2957473",
            "ntype": "s",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            },
            "src_ix": "9-662_v1_77",
            "start": 0,
            "end": 284,
            "label": {}
        },
        {
            "ix": "9-662_v1_78@0",
            "content": "<REF-138> Agulnik M Tannir NM Pressey JG : A phase II, multicenter study of the EZH2 inhibitor tazemetostat in adult subjects with INI1-negative tumors or relapsed/refractory synovial sarcoma. J Clin Oncol. 2016 ; 34 ( 15_suppl ): TPS11071 \u2013 TPS11071 . (suppl; abstr TPS11071). 10.1200/JCO.2016.34.15_suppl.TPS11071",
            "ntype": "s",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            },
            "src_ix": "9-662_v1_78",
            "start": 0,
            "end": 314,
            "label": {}
        },
        {
            "ix": "9-662_v1_79@0",
            "content": "<REF-139> Wilson BG Wang X Shen X : Epigenetic antagonism between polycomb and SWI/SNF complexes during oncogenic transformation . [published correction appears in Cancer Cell. 2011 Jan 18; 19(1): 153] Cancer Cell. 2010 ; 18 ( 4 ): 316 \u2013 28 . 20951942 10.1016/j.ccr.2010.09.006 2957473",
            "ntype": "s",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            },
            "src_ix": "9-662_v1_79",
            "start": 0,
            "end": 284,
            "label": {}
        },
        {
            "ix": "9-662_v1_80@0",
            "content": "<REF-140> Msaouel P Carugo A Genovese G : Targeting proteostasis and autophagy in SMARCB1-deficient malignancies: where next? Oncotarget. 2019 ; 10 ( 40 ): 3979 \u2013 3981 . 31258836 10.18632/oncotarget.26970 6592295",
            "ntype": "s",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            },
            "src_ix": "9-662_v1_80",
            "start": 0,
            "end": 211,
            "label": {}
        },
        {
            "ix": "9-662_v1_81@0",
            "content": "<REF-141> Msaouel P Slack-Tidwell R Genovese G : Phase II trial of ixazomib combined with gemcitabine and doxorubicin in patients with SMARCB1-deficient kidney malignancies. J Clin Oncol. 2019 ; 37 ( 7_suppl ): (suppl; abstr TPS678\u2013TPS678). 10.1200/JCO.2019.37.7_suppl.TPS678",
            "ntype": "s",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            },
            "src_ix": "9-662_v1_81",
            "start": 0,
            "end": 274,
            "label": {}
        }
    ],
    "edges": [
        {
            "src_ix": "9-662_v1_0",
            "tgt_ix": "9-662_v1_1",
            "etype": "parent",
            "meta": {
                "created_by": "F1000XMLParser"
            }
        },
        {
            "src_ix": "9-662_v1_1",
            "tgt_ix": "9-662_v1_2",
            "etype": "parent",
            "meta": {
                "created_by": "F1000XMLParser"
            }
        },
        {
            "src_ix": "9-662_v1_0",
            "tgt_ix": "9-662_v1_3",
            "etype": "parent",
            "meta": {
                "created_by": "F1000XMLParser"
            }
        },
        {
            "src_ix": "9-662_v1_3",
            "tgt_ix": "9-662_v1_4",
            "etype": "parent",
            "meta": {
                "created_by": "F1000XMLParser"
            }
        },
        {
            "src_ix": "9-662_v1_3",
            "tgt_ix": "9-662_v1_5",
            "etype": "parent",
            "meta": {
                "created_by": "F1000XMLParser"
            }
        },
        {
            "src_ix": "9-662_v1_0",
            "tgt_ix": "9-662_v1_6",
            "etype": "parent",
            "meta": {
                "created_by": "F1000XMLParser"
            }
        },
        {
            "src_ix": "9-662_v1_6",
            "tgt_ix": "9-662_v1_7",
            "etype": "parent",
            "meta": {
                "created_by": "F1000XMLParser"
            }
        },
        {
            "src_ix": "9-662_v1_6",
            "tgt_ix": "9-662_v1_8",
            "etype": "parent",
            "meta": {
                "created_by": "F1000XMLParser"
            }
        },
        {
            "src_ix": "9-662_v1_8",
            "tgt_ix": "9-662_v1_9",
            "etype": "parent",
            "meta": {
                "created_by": "F1000XMLParser"
            }
        },
        {
            "src_ix": "9-662_v1_6",
            "tgt_ix": "9-662_v1_10",
            "etype": "parent",
            "meta": {
                "created_by": "F1000XMLParser"
            }
        },
        {
            "src_ix": "9-662_v1_6",
            "tgt_ix": "9-662_v1_11",
            "etype": "parent",
            "meta": {
                "created_by": "F1000XMLParser"
            }
        },
        {
            "src_ix": "9-662_v1_6",
            "tgt_ix": "9-662_v1_12",
            "etype": "parent",
            "meta": {
                "created_by": "F1000XMLParser"
            }
        },
        {
            "src_ix": "9-662_v1_0",
            "tgt_ix": "9-662_v1_13",
            "etype": "parent",
            "meta": {
                "created_by": "F1000XMLParser"
            }
        },
        {
            "src_ix": "9-662_v1_13",
            "tgt_ix": "9-662_v1_14",
            "etype": "parent",
            "meta": {
                "created_by": "F1000XMLParser"
            }
        },
        {
            "src_ix": "9-662_v1_13",
            "tgt_ix": "9-662_v1_15",
            "etype": "parent",
            "meta": {
                "created_by": "F1000XMLParser"
            }
        },
        {
            "src_ix": "9-662_v1_15",
            "tgt_ix": "9-662_v1_16",
            "etype": "parent",
            "meta": {
                "created_by": "F1000XMLParser"
            }
        },
        {
            "src_ix": "9-662_v1_13",
            "tgt_ix": "9-662_v1_17",
            "etype": "parent",
            "meta": {
                "created_by": "F1000XMLParser"
            }
        },
        {
            "src_ix": "9-662_v1_13",
            "tgt_ix": "9-662_v1_18",
            "etype": "parent",
            "meta": {
                "created_by": "F1000XMLParser"
            }
        },
        {
            "src_ix": "9-662_v1_18",
            "tgt_ix": "9-662_v1_19",
            "etype": "parent",
            "meta": {
                "created_by": "F1000XMLParser"
            }
        },
        {
            "src_ix": "9-662_v1_0",
            "tgt_ix": "9-662_v1_20",
            "etype": "parent",
            "meta": {
                "created_by": "F1000XMLParser"
            }
        },
        {
            "src_ix": "9-662_v1_20",
            "tgt_ix": "9-662_v1_21",
            "etype": "parent",
            "meta": {
                "created_by": "F1000XMLParser"
            }
        },
        {
            "src_ix": "9-662_v1_20",
            "tgt_ix": "9-662_v1_22",
            "etype": "parent",
            "meta": {
                "created_by": "F1000XMLParser"
            }
        },
        {
            "src_ix": "9-662_v1_22",
            "tgt_ix": "9-662_v1_23",
            "etype": "parent",
            "meta": {
                "created_by": "F1000XMLParser"
            }
        },
        {
            "src_ix": "9-662_v1_20",
            "tgt_ix": "9-662_v1_24",
            "etype": "parent",
            "meta": {
                "created_by": "F1000XMLParser"
            }
        },
        {
            "src_ix": "9-662_v1_20",
            "tgt_ix": "9-662_v1_25",
            "etype": "parent",
            "meta": {
                "created_by": "F1000XMLParser"
            }
        },
        {
            "src_ix": "9-662_v1_20",
            "tgt_ix": "9-662_v1_26",
            "etype": "parent",
            "meta": {
                "created_by": "F1000XMLParser"
            }
        },
        {
            "src_ix": "9-662_v1_0",
            "tgt_ix": "9-662_v1_27",
            "etype": "parent",
            "meta": {
                "created_by": "F1000XMLParser"
            }
        },
        {
            "src_ix": "9-662_v1_27",
            "tgt_ix": "9-662_v1_28",
            "etype": "parent",
            "meta": {
                "created_by": "F1000XMLParser"
            }
        },
        {
            "src_ix": "9-662_v1_28",
            "tgt_ix": "9-662_v1_29",
            "etype": "parent",
            "meta": {
                "created_by": "F1000XMLParser"
            }
        },
        {
            "src_ix": "9-662_v1_0",
            "tgt_ix": "9-662_v1_1",
            "etype": "next",
            "meta": {
                "created_by": "F1000XMLParser"
            }
        },
        {
            "src_ix": "9-662_v1_1",
            "tgt_ix": "9-662_v1_2",
            "etype": "next",
            "meta": {
                "created_by": "F1000XMLParser"
            }
        },
        {
            "src_ix": "9-662_v1_2",
            "tgt_ix": "9-662_v1_3",
            "etype": "next",
            "meta": {
                "created_by": "F1000XMLParser"
            }
        },
        {
            "src_ix": "9-662_v1_3",
            "tgt_ix": "9-662_v1_4",
            "etype": "next",
            "meta": {
                "created_by": "F1000XMLParser"
            }
        },
        {
            "src_ix": "9-662_v1_4",
            "tgt_ix": "9-662_v1_5",
            "etype": "next",
            "meta": {
                "created_by": "F1000XMLParser"
            }
        },
        {
            "src_ix": "9-662_v1_5",
            "tgt_ix": "9-662_v1_6",
            "etype": "next",
            "meta": {
                "created_by": "F1000XMLParser"
            }
        },
        {
            "src_ix": "9-662_v1_6",
            "tgt_ix": "9-662_v1_7",
            "etype": "next",
            "meta": {
                "created_by": "F1000XMLParser"
            }
        },
        {
            "src_ix": "9-662_v1_7",
            "tgt_ix": "9-662_v1_8",
            "etype": "next",
            "meta": {
                "created_by": "F1000XMLParser"
            }
        },
        {
            "src_ix": "9-662_v1_8",
            "tgt_ix": "9-662_v1_9",
            "etype": "next",
            "meta": {
                "created_by": "F1000XMLParser"
            }
        },
        {
            "src_ix": "9-662_v1_9",
            "tgt_ix": "9-662_v1_10",
            "etype": "next",
            "meta": {
                "created_by": "F1000XMLParser"
            }
        },
        {
            "src_ix": "9-662_v1_10",
            "tgt_ix": "9-662_v1_11",
            "etype": "next",
            "meta": {
                "created_by": "F1000XMLParser"
            }
        },
        {
            "src_ix": "9-662_v1_11",
            "tgt_ix": "9-662_v1_12",
            "etype": "next",
            "meta": {
                "created_by": "F1000XMLParser"
            }
        },
        {
            "src_ix": "9-662_v1_12",
            "tgt_ix": "9-662_v1_13",
            "etype": "next",
            "meta": {
                "created_by": "F1000XMLParser"
            }
        },
        {
            "src_ix": "9-662_v1_13",
            "tgt_ix": "9-662_v1_14",
            "etype": "next",
            "meta": {
                "created_by": "F1000XMLParser"
            }
        },
        {
            "src_ix": "9-662_v1_14",
            "tgt_ix": "9-662_v1_15",
            "etype": "next",
            "meta": {
                "created_by": "F1000XMLParser"
            }
        },
        {
            "src_ix": "9-662_v1_15",
            "tgt_ix": "9-662_v1_16",
            "etype": "next",
            "meta": {
                "created_by": "F1000XMLParser"
            }
        },
        {
            "src_ix": "9-662_v1_16",
            "tgt_ix": "9-662_v1_17",
            "etype": "next",
            "meta": {
                "created_by": "F1000XMLParser"
            }
        },
        {
            "src_ix": "9-662_v1_17",
            "tgt_ix": "9-662_v1_18",
            "etype": "next",
            "meta": {
                "created_by": "F1000XMLParser"
            }
        },
        {
            "src_ix": "9-662_v1_18",
            "tgt_ix": "9-662_v1_19",
            "etype": "next",
            "meta": {
                "created_by": "F1000XMLParser"
            }
        },
        {
            "src_ix": "9-662_v1_19",
            "tgt_ix": "9-662_v1_20",
            "etype": "next",
            "meta": {
                "created_by": "F1000XMLParser"
            }
        },
        {
            "src_ix": "9-662_v1_20",
            "tgt_ix": "9-662_v1_21",
            "etype": "next",
            "meta": {
                "created_by": "F1000XMLParser"
            }
        },
        {
            "src_ix": "9-662_v1_21",
            "tgt_ix": "9-662_v1_22",
            "etype": "next",
            "meta": {
                "created_by": "F1000XMLParser"
            }
        },
        {
            "src_ix": "9-662_v1_22",
            "tgt_ix": "9-662_v1_23",
            "etype": "next",
            "meta": {
                "created_by": "F1000XMLParser"
            }
        },
        {
            "src_ix": "9-662_v1_23",
            "tgt_ix": "9-662_v1_24",
            "etype": "next",
            "meta": {
                "created_by": "F1000XMLParser"
            }
        },
        {
            "src_ix": "9-662_v1_24",
            "tgt_ix": "9-662_v1_25",
            "etype": "next",
            "meta": {
                "created_by": "F1000XMLParser"
            }
        },
        {
            "src_ix": "9-662_v1_25",
            "tgt_ix": "9-662_v1_26",
            "etype": "next",
            "meta": {
                "created_by": "F1000XMLParser"
            }
        },
        {
            "src_ix": "9-662_v1_26",
            "tgt_ix": "9-662_v1_27",
            "etype": "next",
            "meta": {
                "created_by": "F1000XMLParser"
            }
        },
        {
            "src_ix": "9-662_v1_27",
            "tgt_ix": "9-662_v1_28",
            "etype": "next",
            "meta": {
                "created_by": "F1000XMLParser"
            }
        },
        {
            "src_ix": "9-662_v1_28",
            "tgt_ix": "9-662_v1_29",
            "etype": "next",
            "meta": {
                "created_by": "F1000XMLParser"
            }
        },
        {
            "src_ix": "9-662_v1_4",
            "tgt_ix": "9-662_v1_30",
            "etype": "link",
            "meta": {
                "created_by": "F1000XMLParser"
            }
        },
        {
            "src_ix": "9-662_v1_4",
            "tgt_ix": "9-662_v1_31",
            "etype": "link",
            "meta": {
                "created_by": "F1000XMLParser"
            }
        },
        {
            "src_ix": "9-662_v1_4",
            "tgt_ix": "9-662_v1_32",
            "etype": "link",
            "meta": {
                "created_by": "F1000XMLParser"
            }
        },
        {
            "src_ix": "9-662_v1_4",
            "tgt_ix": "9-662_v1_33",
            "etype": "link",
            "meta": {
                "created_by": "F1000XMLParser"
            }
        },
        {
            "src_ix": "9-662_v1_4",
            "tgt_ix": "9-662_v1_34",
            "etype": "link",
            "meta": {
                "created_by": "F1000XMLParser"
            }
        },
        {
            "src_ix": "9-662_v1_4",
            "tgt_ix": "9-662_v1_35",
            "etype": "link",
            "meta": {
                "created_by": "F1000XMLParser"
            }
        },
        {
            "src_ix": "9-662_v1_4",
            "tgt_ix": "9-662_v1_36",
            "etype": "link",
            "meta": {
                "created_by": "F1000XMLParser"
            }
        },
        {
            "src_ix": "9-662_v1_4",
            "tgt_ix": "9-662_v1_37",
            "etype": "link",
            "meta": {
                "created_by": "F1000XMLParser"
            }
        },
        {
            "src_ix": "9-662_v1_7",
            "tgt_ix": "9-662_v1_38",
            "etype": "link",
            "meta": {
                "created_by": "F1000XMLParser"
            }
        },
        {
            "src_ix": "9-662_v1_11",
            "tgt_ix": "9-662_v1_39",
            "etype": "link",
            "meta": {
                "created_by": "F1000XMLParser"
            }
        },
        {
            "src_ix": "9-662_v1_7",
            "tgt_ix": "9-662_v1_40",
            "etype": "link",
            "meta": {
                "created_by": "F1000XMLParser"
            }
        },
        {
            "src_ix": "9-662_v1_7",
            "tgt_ix": "9-662_v1_41",
            "etype": "link",
            "meta": {
                "created_by": "F1000XMLParser"
            }
        },
        {
            "src_ix": "9-662_v1_11",
            "tgt_ix": "9-662_v1_42",
            "etype": "link",
            "meta": {
                "created_by": "F1000XMLParser"
            }
        },
        {
            "src_ix": "9-662_v1_11",
            "tgt_ix": "9-662_v1_43",
            "etype": "link",
            "meta": {
                "created_by": "F1000XMLParser"
            }
        },
        {
            "src_ix": "9-662_v1_11",
            "tgt_ix": "9-662_v1_44",
            "etype": "link",
            "meta": {
                "created_by": "F1000XMLParser"
            }
        },
        {
            "src_ix": "9-662_v1_12",
            "tgt_ix": "9-662_v1_45",
            "etype": "link",
            "meta": {
                "created_by": "F1000XMLParser"
            }
        },
        {
            "src_ix": "9-662_v1_12",
            "tgt_ix": "9-662_v1_46",
            "etype": "link",
            "meta": {
                "created_by": "F1000XMLParser"
            }
        },
        {
            "src_ix": "9-662_v1_7",
            "tgt_ix": "9-662_v1_47",
            "etype": "link",
            "meta": {
                "created_by": "F1000XMLParser"
            }
        },
        {
            "src_ix": "9-662_v1_7",
            "tgt_ix": "9-662_v1_48",
            "etype": "link",
            "meta": {
                "created_by": "F1000XMLParser"
            }
        },
        {
            "src_ix": "9-662_v1_7",
            "tgt_ix": "9-662_v1_49",
            "etype": "link",
            "meta": {
                "created_by": "F1000XMLParser"
            }
        },
        {
            "src_ix": "9-662_v1_10",
            "tgt_ix": "9-662_v1_50",
            "etype": "link",
            "meta": {
                "created_by": "F1000XMLParser"
            }
        },
        {
            "src_ix": "9-662_v1_10",
            "tgt_ix": "9-662_v1_51",
            "etype": "link",
            "meta": {
                "created_by": "F1000XMLParser"
            }
        },
        {
            "src_ix": "9-662_v1_11",
            "tgt_ix": "9-662_v1_52",
            "etype": "link",
            "meta": {
                "created_by": "F1000XMLParser"
            }
        },
        {
            "src_ix": "9-662_v1_11",
            "tgt_ix": "9-662_v1_53",
            "etype": "link",
            "meta": {
                "created_by": "F1000XMLParser"
            }
        },
        {
            "src_ix": "9-662_v1_11",
            "tgt_ix": "9-662_v1_54",
            "etype": "link",
            "meta": {
                "created_by": "F1000XMLParser"
            }
        },
        {
            "src_ix": "9-662_v1_11",
            "tgt_ix": "9-662_v1_55",
            "etype": "link",
            "meta": {
                "created_by": "F1000XMLParser"
            }
        },
        {
            "src_ix": "9-662_v1_14",
            "tgt_ix": "9-662_v1_56",
            "etype": "link",
            "meta": {
                "created_by": "F1000XMLParser"
            }
        },
        {
            "src_ix": "9-662_v1_14",
            "tgt_ix": "9-662_v1_57",
            "etype": "link",
            "meta": {
                "created_by": "F1000XMLParser"
            }
        },
        {
            "src_ix": "9-662_v1_14",
            "tgt_ix": "9-662_v1_58",
            "etype": "link",
            "meta": {
                "created_by": "F1000XMLParser"
            }
        },
        {
            "src_ix": "9-662_v1_17",
            "tgt_ix": "9-662_v1_59",
            "etype": "link",
            "meta": {
                "created_by": "F1000XMLParser"
            }
        },
        {
            "src_ix": "9-662_v1_17",
            "tgt_ix": "9-662_v1_60",
            "etype": "link",
            "meta": {
                "created_by": "F1000XMLParser"
            }
        },
        {
            "src_ix": "9-662_v1_21",
            "tgt_ix": "9-662_v1_61",
            "etype": "link",
            "meta": {
                "created_by": "F1000XMLParser"
            }
        },
        {
            "src_ix": "9-662_v1_21",
            "tgt_ix": "9-662_v1_62",
            "etype": "link",
            "meta": {
                "created_by": "F1000XMLParser"
            }
        },
        {
            "src_ix": "9-662_v1_21",
            "tgt_ix": "9-662_v1_63",
            "etype": "link",
            "meta": {
                "created_by": "F1000XMLParser"
            }
        },
        {
            "src_ix": "9-662_v1_21",
            "tgt_ix": "9-662_v1_64",
            "etype": "link",
            "meta": {
                "created_by": "F1000XMLParser"
            }
        },
        {
            "src_ix": "9-662_v1_21",
            "tgt_ix": "9-662_v1_65",
            "etype": "link",
            "meta": {
                "created_by": "F1000XMLParser"
            }
        },
        {
            "src_ix": "9-662_v1_21",
            "tgt_ix": "9-662_v1_66",
            "etype": "link",
            "meta": {
                "created_by": "F1000XMLParser"
            }
        },
        {
            "src_ix": "9-662_v1_21",
            "tgt_ix": "9-662_v1_67",
            "etype": "link",
            "meta": {
                "created_by": "F1000XMLParser"
            }
        },
        {
            "src_ix": "9-662_v1_24",
            "tgt_ix": "9-662_v1_68",
            "etype": "link",
            "meta": {
                "created_by": "F1000XMLParser"
            }
        },
        {
            "src_ix": "9-662_v1_24",
            "tgt_ix": "9-662_v1_69",
            "etype": "link",
            "meta": {
                "created_by": "F1000XMLParser"
            }
        },
        {
            "src_ix": "9-662_v1_24",
            "tgt_ix": "9-662_v1_70",
            "etype": "link",
            "meta": {
                "created_by": "F1000XMLParser"
            }
        },
        {
            "src_ix": "9-662_v1_24",
            "tgt_ix": "9-662_v1_71",
            "etype": "link",
            "meta": {
                "created_by": "F1000XMLParser"
            }
        },
        {
            "src_ix": "9-662_v1_24",
            "tgt_ix": "9-662_v1_72",
            "etype": "link",
            "meta": {
                "created_by": "F1000XMLParser"
            }
        },
        {
            "src_ix": "9-662_v1_24",
            "tgt_ix": "9-662_v1_73",
            "etype": "link",
            "meta": {
                "created_by": "F1000XMLParser"
            }
        },
        {
            "src_ix": "9-662_v1_25",
            "tgt_ix": "9-662_v1_74",
            "etype": "link",
            "meta": {
                "created_by": "F1000XMLParser"
            }
        },
        {
            "src_ix": "9-662_v1_25",
            "tgt_ix": "9-662_v1_75",
            "etype": "link",
            "meta": {
                "created_by": "F1000XMLParser"
            }
        },
        {
            "src_ix": "9-662_v1_25",
            "tgt_ix": "9-662_v1_76",
            "etype": "link",
            "meta": {
                "created_by": "F1000XMLParser"
            }
        },
        {
            "src_ix": "9-662_v1_26",
            "tgt_ix": "9-662_v1_77",
            "etype": "link",
            "meta": {
                "created_by": "F1000XMLParser"
            }
        },
        {
            "src_ix": "9-662_v1_26",
            "tgt_ix": "9-662_v1_78",
            "etype": "link",
            "meta": {
                "created_by": "F1000XMLParser"
            }
        },
        {
            "src_ix": "9-662_v1_26",
            "tgt_ix": "9-662_v1_79",
            "etype": "link",
            "meta": {
                "created_by": "F1000XMLParser"
            }
        },
        {
            "src_ix": "9-662_v1_26",
            "tgt_ix": "9-662_v1_80",
            "etype": "link",
            "meta": {
                "created_by": "F1000XMLParser"
            }
        },
        {
            "src_ix": "9-662_v1_26",
            "tgt_ix": "9-662_v1_81",
            "etype": "link",
            "meta": {
                "created_by": "F1000XMLParser"
            }
        },
        {
            "src_ix": "9-662_v1_7",
            "tgt_ix": "9-662_v1_9",
            "etype": "link",
            "meta": {
                "created_by": "F1000XMLParser"
            }
        },
        {
            "src_ix": "9-662_v1_14",
            "tgt_ix": "9-662_v1_16",
            "etype": "link",
            "meta": {
                "created_by": "F1000XMLParser"
            }
        },
        {
            "src_ix": "9-662_v1_17",
            "tgt_ix": "9-662_v1_19",
            "etype": "link",
            "meta": {
                "created_by": "F1000XMLParser"
            }
        },
        {
            "src_ix": "9-662_v1_21",
            "tgt_ix": "9-662_v1_23",
            "etype": "link",
            "meta": {
                "created_by": "F1000XMLParser"
            }
        },
        {
            "src_ix": "9-662_v1_0",
            "tgt_ix": "9-662_v1_0@0",
            "etype": "link",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            }
        },
        {
            "src_ix": "9-662_v1_1",
            "tgt_ix": "9-662_v1_1@0",
            "etype": "link",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            }
        },
        {
            "src_ix": "9-662_v1_2",
            "tgt_ix": "9-662_v1_2@0",
            "etype": "link",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            }
        },
        {
            "src_ix": "9-662_v1_2",
            "tgt_ix": "9-662_v1_2@1",
            "etype": "link",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            }
        },
        {
            "src_ix": "9-662_v1_2",
            "tgt_ix": "9-662_v1_2@2",
            "etype": "link",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            }
        },
        {
            "src_ix": "9-662_v1_2",
            "tgt_ix": "9-662_v1_2@3",
            "etype": "link",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            }
        },
        {
            "src_ix": "9-662_v1_2",
            "tgt_ix": "9-662_v1_2@4",
            "etype": "link",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            }
        },
        {
            "src_ix": "9-662_v1_2",
            "tgt_ix": "9-662_v1_2@5",
            "etype": "link",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            }
        },
        {
            "src_ix": "9-662_v1_2",
            "tgt_ix": "9-662_v1_2@6",
            "etype": "link",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            }
        },
        {
            "src_ix": "9-662_v1_2",
            "tgt_ix": "9-662_v1_2@7",
            "etype": "link",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            }
        },
        {
            "src_ix": "9-662_v1_2",
            "tgt_ix": "9-662_v1_2@8",
            "etype": "link",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            }
        },
        {
            "src_ix": "9-662_v1_3",
            "tgt_ix": "9-662_v1_3@0",
            "etype": "link",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            }
        },
        {
            "src_ix": "9-662_v1_4",
            "tgt_ix": "9-662_v1_4@0",
            "etype": "link",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            }
        },
        {
            "src_ix": "9-662_v1_4",
            "tgt_ix": "9-662_v1_4@1",
            "etype": "link",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            }
        },
        {
            "src_ix": "9-662_v1_4",
            "tgt_ix": "9-662_v1_4@2",
            "etype": "link",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            }
        },
        {
            "src_ix": "9-662_v1_4",
            "tgt_ix": "9-662_v1_4@3",
            "etype": "link",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            }
        },
        {
            "src_ix": "9-662_v1_4",
            "tgt_ix": "9-662_v1_4@4",
            "etype": "link",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            }
        },
        {
            "src_ix": "9-662_v1_4",
            "tgt_ix": "9-662_v1_4@5",
            "etype": "link",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            }
        },
        {
            "src_ix": "9-662_v1_4",
            "tgt_ix": "9-662_v1_4@6",
            "etype": "link",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            }
        },
        {
            "src_ix": "9-662_v1_4",
            "tgt_ix": "9-662_v1_4@7",
            "etype": "link",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            }
        },
        {
            "src_ix": "9-662_v1_4",
            "tgt_ix": "9-662_v1_4@8",
            "etype": "link",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            }
        },
        {
            "src_ix": "9-662_v1_4",
            "tgt_ix": "9-662_v1_4@9",
            "etype": "link",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            }
        },
        {
            "src_ix": "9-662_v1_5",
            "tgt_ix": "9-662_v1_5@0",
            "etype": "link",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            }
        },
        {
            "src_ix": "9-662_v1_5",
            "tgt_ix": "9-662_v1_5@1",
            "etype": "link",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            }
        },
        {
            "src_ix": "9-662_v1_6",
            "tgt_ix": "9-662_v1_6@0",
            "etype": "link",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            }
        },
        {
            "src_ix": "9-662_v1_7",
            "tgt_ix": "9-662_v1_7@0",
            "etype": "link",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            }
        },
        {
            "src_ix": "9-662_v1_7",
            "tgt_ix": "9-662_v1_7@1",
            "etype": "link",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            }
        },
        {
            "src_ix": "9-662_v1_7",
            "tgt_ix": "9-662_v1_7@2",
            "etype": "link",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            }
        },
        {
            "src_ix": "9-662_v1_7",
            "tgt_ix": "9-662_v1_7@3",
            "etype": "link",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            }
        },
        {
            "src_ix": "9-662_v1_7",
            "tgt_ix": "9-662_v1_7@4",
            "etype": "link",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            }
        },
        {
            "src_ix": "9-662_v1_7",
            "tgt_ix": "9-662_v1_7@5",
            "etype": "link",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            }
        },
        {
            "src_ix": "9-662_v1_7",
            "tgt_ix": "9-662_v1_7@6",
            "etype": "link",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            }
        },
        {
            "src_ix": "9-662_v1_8",
            "tgt_ix": "9-662_v1_8@0",
            "etype": "link",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            }
        },
        {
            "src_ix": "9-662_v1_10",
            "tgt_ix": "9-662_v1_10@0",
            "etype": "link",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            }
        },
        {
            "src_ix": "9-662_v1_10",
            "tgt_ix": "9-662_v1_10@1",
            "etype": "link",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            }
        },
        {
            "src_ix": "9-662_v1_10",
            "tgt_ix": "9-662_v1_10@2",
            "etype": "link",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            }
        },
        {
            "src_ix": "9-662_v1_10",
            "tgt_ix": "9-662_v1_10@3",
            "etype": "link",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            }
        },
        {
            "src_ix": "9-662_v1_10",
            "tgt_ix": "9-662_v1_10@4",
            "etype": "link",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            }
        },
        {
            "src_ix": "9-662_v1_10",
            "tgt_ix": "9-662_v1_10@5",
            "etype": "link",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            }
        },
        {
            "src_ix": "9-662_v1_11",
            "tgt_ix": "9-662_v1_11@0",
            "etype": "link",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            }
        },
        {
            "src_ix": "9-662_v1_11",
            "tgt_ix": "9-662_v1_11@1",
            "etype": "link",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            }
        },
        {
            "src_ix": "9-662_v1_11",
            "tgt_ix": "9-662_v1_11@2",
            "etype": "link",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            }
        },
        {
            "src_ix": "9-662_v1_11",
            "tgt_ix": "9-662_v1_11@3",
            "etype": "link",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            }
        },
        {
            "src_ix": "9-662_v1_11",
            "tgt_ix": "9-662_v1_11@4",
            "etype": "link",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            }
        },
        {
            "src_ix": "9-662_v1_11",
            "tgt_ix": "9-662_v1_11@5",
            "etype": "link",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            }
        },
        {
            "src_ix": "9-662_v1_11",
            "tgt_ix": "9-662_v1_11@6",
            "etype": "link",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            }
        },
        {
            "src_ix": "9-662_v1_11",
            "tgt_ix": "9-662_v1_11@7",
            "etype": "link",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            }
        },
        {
            "src_ix": "9-662_v1_11",
            "tgt_ix": "9-662_v1_11@8",
            "etype": "link",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            }
        },
        {
            "src_ix": "9-662_v1_11",
            "tgt_ix": "9-662_v1_11@9",
            "etype": "link",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            }
        },
        {
            "src_ix": "9-662_v1_12",
            "tgt_ix": "9-662_v1_12@0",
            "etype": "link",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            }
        },
        {
            "src_ix": "9-662_v1_12",
            "tgt_ix": "9-662_v1_12@1",
            "etype": "link",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            }
        },
        {
            "src_ix": "9-662_v1_12",
            "tgt_ix": "9-662_v1_12@2",
            "etype": "link",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            }
        },
        {
            "src_ix": "9-662_v1_12",
            "tgt_ix": "9-662_v1_12@3",
            "etype": "link",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            }
        },
        {
            "src_ix": "9-662_v1_12",
            "tgt_ix": "9-662_v1_12@4",
            "etype": "link",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            }
        },
        {
            "src_ix": "9-662_v1_12",
            "tgt_ix": "9-662_v1_12@5",
            "etype": "link",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            }
        },
        {
            "src_ix": "9-662_v1_12",
            "tgt_ix": "9-662_v1_12@6",
            "etype": "link",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            }
        },
        {
            "src_ix": "9-662_v1_13",
            "tgt_ix": "9-662_v1_13@0",
            "etype": "link",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            }
        },
        {
            "src_ix": "9-662_v1_14",
            "tgt_ix": "9-662_v1_14@0",
            "etype": "link",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            }
        },
        {
            "src_ix": "9-662_v1_14",
            "tgt_ix": "9-662_v1_14@1",
            "etype": "link",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            }
        },
        {
            "src_ix": "9-662_v1_14",
            "tgt_ix": "9-662_v1_14@2",
            "etype": "link",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            }
        },
        {
            "src_ix": "9-662_v1_14",
            "tgt_ix": "9-662_v1_14@3",
            "etype": "link",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            }
        },
        {
            "src_ix": "9-662_v1_14",
            "tgt_ix": "9-662_v1_14@4",
            "etype": "link",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            }
        },
        {
            "src_ix": "9-662_v1_14",
            "tgt_ix": "9-662_v1_14@5",
            "etype": "link",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            }
        },
        {
            "src_ix": "9-662_v1_14",
            "tgt_ix": "9-662_v1_14@6",
            "etype": "link",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            }
        },
        {
            "src_ix": "9-662_v1_15",
            "tgt_ix": "9-662_v1_15@0",
            "etype": "link",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            }
        },
        {
            "src_ix": "9-662_v1_17",
            "tgt_ix": "9-662_v1_17@0",
            "etype": "link",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            }
        },
        {
            "src_ix": "9-662_v1_17",
            "tgt_ix": "9-662_v1_17@1",
            "etype": "link",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            }
        },
        {
            "src_ix": "9-662_v1_17",
            "tgt_ix": "9-662_v1_17@2",
            "etype": "link",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            }
        },
        {
            "src_ix": "9-662_v1_17",
            "tgt_ix": "9-662_v1_17@3",
            "etype": "link",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            }
        },
        {
            "src_ix": "9-662_v1_17",
            "tgt_ix": "9-662_v1_17@4",
            "etype": "link",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            }
        },
        {
            "src_ix": "9-662_v1_17",
            "tgt_ix": "9-662_v1_17@5",
            "etype": "link",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            }
        },
        {
            "src_ix": "9-662_v1_18",
            "tgt_ix": "9-662_v1_18@0",
            "etype": "link",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            }
        },
        {
            "src_ix": "9-662_v1_20",
            "tgt_ix": "9-662_v1_20@0",
            "etype": "link",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            }
        },
        {
            "src_ix": "9-662_v1_21",
            "tgt_ix": "9-662_v1_21@0",
            "etype": "link",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            }
        },
        {
            "src_ix": "9-662_v1_21",
            "tgt_ix": "9-662_v1_21@1",
            "etype": "link",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            }
        },
        {
            "src_ix": "9-662_v1_21",
            "tgt_ix": "9-662_v1_21@2",
            "etype": "link",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            }
        },
        {
            "src_ix": "9-662_v1_21",
            "tgt_ix": "9-662_v1_21@3",
            "etype": "link",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            }
        },
        {
            "src_ix": "9-662_v1_21",
            "tgt_ix": "9-662_v1_21@4",
            "etype": "link",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            }
        },
        {
            "src_ix": "9-662_v1_21",
            "tgt_ix": "9-662_v1_21@5",
            "etype": "link",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            }
        },
        {
            "src_ix": "9-662_v1_21",
            "tgt_ix": "9-662_v1_21@6",
            "etype": "link",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            }
        },
        {
            "src_ix": "9-662_v1_21",
            "tgt_ix": "9-662_v1_21@7",
            "etype": "link",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            }
        },
        {
            "src_ix": "9-662_v1_21",
            "tgt_ix": "9-662_v1_21@8",
            "etype": "link",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            }
        },
        {
            "src_ix": "9-662_v1_21",
            "tgt_ix": "9-662_v1_21@9",
            "etype": "link",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            }
        },
        {
            "src_ix": "9-662_v1_22",
            "tgt_ix": "9-662_v1_22@0",
            "etype": "link",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            }
        },
        {
            "src_ix": "9-662_v1_24",
            "tgt_ix": "9-662_v1_24@0",
            "etype": "link",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            }
        },
        {
            "src_ix": "9-662_v1_24",
            "tgt_ix": "9-662_v1_24@1",
            "etype": "link",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            }
        },
        {
            "src_ix": "9-662_v1_24",
            "tgt_ix": "9-662_v1_24@2",
            "etype": "link",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            }
        },
        {
            "src_ix": "9-662_v1_24",
            "tgt_ix": "9-662_v1_24@3",
            "etype": "link",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            }
        },
        {
            "src_ix": "9-662_v1_24",
            "tgt_ix": "9-662_v1_24@4",
            "etype": "link",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            }
        },
        {
            "src_ix": "9-662_v1_24",
            "tgt_ix": "9-662_v1_24@5",
            "etype": "link",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            }
        },
        {
            "src_ix": "9-662_v1_25",
            "tgt_ix": "9-662_v1_25@0",
            "etype": "link",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            }
        },
        {
            "src_ix": "9-662_v1_25",
            "tgt_ix": "9-662_v1_25@1",
            "etype": "link",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            }
        },
        {
            "src_ix": "9-662_v1_25",
            "tgt_ix": "9-662_v1_25@2",
            "etype": "link",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            }
        },
        {
            "src_ix": "9-662_v1_25",
            "tgt_ix": "9-662_v1_25@3",
            "etype": "link",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            }
        },
        {
            "src_ix": "9-662_v1_26",
            "tgt_ix": "9-662_v1_26@0",
            "etype": "link",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            }
        },
        {
            "src_ix": "9-662_v1_26",
            "tgt_ix": "9-662_v1_26@1",
            "etype": "link",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            }
        },
        {
            "src_ix": "9-662_v1_26",
            "tgt_ix": "9-662_v1_26@2",
            "etype": "link",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            }
        },
        {
            "src_ix": "9-662_v1_26",
            "tgt_ix": "9-662_v1_26@3",
            "etype": "link",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            }
        },
        {
            "src_ix": "9-662_v1_26",
            "tgt_ix": "9-662_v1_26@4",
            "etype": "link",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            }
        },
        {
            "src_ix": "9-662_v1_26",
            "tgt_ix": "9-662_v1_26@5",
            "etype": "link",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            }
        },
        {
            "src_ix": "9-662_v1_27",
            "tgt_ix": "9-662_v1_27@0",
            "etype": "link",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            }
        },
        {
            "src_ix": "9-662_v1_28",
            "tgt_ix": "9-662_v1_28@0",
            "etype": "link",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            }
        },
        {
            "src_ix": "9-662_v1_29",
            "tgt_ix": "9-662_v1_29@0",
            "etype": "link",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            }
        },
        {
            "src_ix": "9-662_v1_30",
            "tgt_ix": "9-662_v1_30@0",
            "etype": "link",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            }
        },
        {
            "src_ix": "9-662_v1_31",
            "tgt_ix": "9-662_v1_31@0",
            "etype": "link",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            }
        },
        {
            "src_ix": "9-662_v1_32",
            "tgt_ix": "9-662_v1_32@0",
            "etype": "link",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            }
        },
        {
            "src_ix": "9-662_v1_33",
            "tgt_ix": "9-662_v1_33@0",
            "etype": "link",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            }
        },
        {
            "src_ix": "9-662_v1_34",
            "tgt_ix": "9-662_v1_34@0",
            "etype": "link",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            }
        },
        {
            "src_ix": "9-662_v1_35",
            "tgt_ix": "9-662_v1_35@0",
            "etype": "link",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            }
        },
        {
            "src_ix": "9-662_v1_36",
            "tgt_ix": "9-662_v1_36@0",
            "etype": "link",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            }
        },
        {
            "src_ix": "9-662_v1_37",
            "tgt_ix": "9-662_v1_37@0",
            "etype": "link",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            }
        },
        {
            "src_ix": "9-662_v1_38",
            "tgt_ix": "9-662_v1_38@0",
            "etype": "link",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            }
        },
        {
            "src_ix": "9-662_v1_39",
            "tgt_ix": "9-662_v1_39@0",
            "etype": "link",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            }
        },
        {
            "src_ix": "9-662_v1_40",
            "tgt_ix": "9-662_v1_40@0",
            "etype": "link",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            }
        },
        {
            "src_ix": "9-662_v1_41",
            "tgt_ix": "9-662_v1_41@0",
            "etype": "link",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            }
        },
        {
            "src_ix": "9-662_v1_42",
            "tgt_ix": "9-662_v1_42@0",
            "etype": "link",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            }
        },
        {
            "src_ix": "9-662_v1_43",
            "tgt_ix": "9-662_v1_43@0",
            "etype": "link",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            }
        },
        {
            "src_ix": "9-662_v1_44",
            "tgt_ix": "9-662_v1_44@0",
            "etype": "link",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            }
        },
        {
            "src_ix": "9-662_v1_45",
            "tgt_ix": "9-662_v1_45@0",
            "etype": "link",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            }
        },
        {
            "src_ix": "9-662_v1_46",
            "tgt_ix": "9-662_v1_46@0",
            "etype": "link",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            }
        },
        {
            "src_ix": "9-662_v1_47",
            "tgt_ix": "9-662_v1_47@0",
            "etype": "link",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            }
        },
        {
            "src_ix": "9-662_v1_48",
            "tgt_ix": "9-662_v1_48@0",
            "etype": "link",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            }
        },
        {
            "src_ix": "9-662_v1_49",
            "tgt_ix": "9-662_v1_49@0",
            "etype": "link",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            }
        },
        {
            "src_ix": "9-662_v1_50",
            "tgt_ix": "9-662_v1_50@0",
            "etype": "link",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            }
        },
        {
            "src_ix": "9-662_v1_51",
            "tgt_ix": "9-662_v1_51@0",
            "etype": "link",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            }
        },
        {
            "src_ix": "9-662_v1_52",
            "tgt_ix": "9-662_v1_52@0",
            "etype": "link",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            }
        },
        {
            "src_ix": "9-662_v1_53",
            "tgt_ix": "9-662_v1_53@0",
            "etype": "link",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            }
        },
        {
            "src_ix": "9-662_v1_54",
            "tgt_ix": "9-662_v1_54@0",
            "etype": "link",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            }
        },
        {
            "src_ix": "9-662_v1_55",
            "tgt_ix": "9-662_v1_55@0",
            "etype": "link",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            }
        },
        {
            "src_ix": "9-662_v1_56",
            "tgt_ix": "9-662_v1_56@0",
            "etype": "link",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            }
        },
        {
            "src_ix": "9-662_v1_57",
            "tgt_ix": "9-662_v1_57@0",
            "etype": "link",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            }
        },
        {
            "src_ix": "9-662_v1_58",
            "tgt_ix": "9-662_v1_58@0",
            "etype": "link",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            }
        },
        {
            "src_ix": "9-662_v1_59",
            "tgt_ix": "9-662_v1_59@0",
            "etype": "link",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            }
        },
        {
            "src_ix": "9-662_v1_60",
            "tgt_ix": "9-662_v1_60@0",
            "etype": "link",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            }
        },
        {
            "src_ix": "9-662_v1_61",
            "tgt_ix": "9-662_v1_61@0",
            "etype": "link",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            }
        },
        {
            "src_ix": "9-662_v1_62",
            "tgt_ix": "9-662_v1_62@0",
            "etype": "link",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            }
        },
        {
            "src_ix": "9-662_v1_63",
            "tgt_ix": "9-662_v1_63@0",
            "etype": "link",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            }
        },
        {
            "src_ix": "9-662_v1_64",
            "tgt_ix": "9-662_v1_64@0",
            "etype": "link",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            }
        },
        {
            "src_ix": "9-662_v1_65",
            "tgt_ix": "9-662_v1_65@0",
            "etype": "link",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            }
        },
        {
            "src_ix": "9-662_v1_66",
            "tgt_ix": "9-662_v1_66@0",
            "etype": "link",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            }
        },
        {
            "src_ix": "9-662_v1_67",
            "tgt_ix": "9-662_v1_67@0",
            "etype": "link",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            }
        },
        {
            "src_ix": "9-662_v1_68",
            "tgt_ix": "9-662_v1_68@0",
            "etype": "link",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            }
        },
        {
            "src_ix": "9-662_v1_69",
            "tgt_ix": "9-662_v1_69@0",
            "etype": "link",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            }
        },
        {
            "src_ix": "9-662_v1_70",
            "tgt_ix": "9-662_v1_70@0",
            "etype": "link",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            }
        },
        {
            "src_ix": "9-662_v1_71",
            "tgt_ix": "9-662_v1_71@0",
            "etype": "link",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            }
        },
        {
            "src_ix": "9-662_v1_72",
            "tgt_ix": "9-662_v1_72@0",
            "etype": "link",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            }
        },
        {
            "src_ix": "9-662_v1_73",
            "tgt_ix": "9-662_v1_73@0",
            "etype": "link",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            }
        },
        {
            "src_ix": "9-662_v1_74",
            "tgt_ix": "9-662_v1_74@0",
            "etype": "link",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            }
        },
        {
            "src_ix": "9-662_v1_75",
            "tgt_ix": "9-662_v1_75@0",
            "etype": "link",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            }
        },
        {
            "src_ix": "9-662_v1_76",
            "tgt_ix": "9-662_v1_76@0",
            "etype": "link",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            }
        },
        {
            "src_ix": "9-662_v1_77",
            "tgt_ix": "9-662_v1_77@0",
            "etype": "link",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            }
        },
        {
            "src_ix": "9-662_v1_78",
            "tgt_ix": "9-662_v1_78@0",
            "etype": "link",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            }
        },
        {
            "src_ix": "9-662_v1_79",
            "tgt_ix": "9-662_v1_79@0",
            "etype": "link",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            }
        },
        {
            "src_ix": "9-662_v1_80",
            "tgt_ix": "9-662_v1_80@0",
            "etype": "link",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            }
        },
        {
            "src_ix": "9-662_v1_81",
            "tgt_ix": "9-662_v1_81@0",
            "etype": "link",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            }
        }
    ],
    "prefix": "9-662_v1",
    "meta": {
        "parser": "F1000XMLParser",
        "intertext-graph": "N/A",
        "doi": "10.12688/f1000research.24808.1",
        "atype": "review",
        "license": "http://creativecommons.org/licenses/by/4.0/",
        "title": "SMARCB1/INI1-deficient tumors of adulthood",
        "abstract": "The SMARCB1/INI1 gene was first discovered in the mid-1990\u2019s, and since then it has been revealed that loss of function mutations in this gene result in aggressive rhabdoid tumors. Recently, the term \u201crhabdoid tumor\u201d has become synonymous with decreased SMARCB1/INI1 expression. When genetic aberrations in the SMARCB1/INI1 gene occur, the result can cause reduced, complete loss, and mosaic expression. Although SMARCB1/INI1-deficient tumors are predominantly sarcomas, this is a diverse group of tumors with mixed phenotypes, which can often make the diagnosis challenging. Prognosis for these aggressive tumors is often poor. Moreover, refractory and relapsing progressive disease is common. As a result, accurate and timely diagnosis is imperative. Despite the SMARCB1/INI1 gene itself and its implications in tumorigenesis being discovered over two decades ago, there is a paucity of rhabdoid tumor cases reported in the literature that detail SMARCB1/INI1 expression. Much work remains if we hope to provide additional therapeutic strategies for patients with aggressive SMARCB1/INI1-deficient tumors.",
        "contributors": [
            {
                "surname": "Parker",
                "given-names": "Nathaniel A."
            },
            {
                "surname": "Al-Obaidi",
                "given-names": "Ammar"
            },
            {
                "surname": "Deutsch",
                "given-names": "Jeremy M."
            }
        ],
        "url": "https://f1000research.com/articles/9-662/v1/",
        "doc_id": "9-662",
        "version": 1,
        "ix_counter": 318,
        "sentence_split_type": "HybridSplitterLessAndLong",
        "sentence_split_model": "HybridSplitterLessAndLong_SciSpacy+Spacy"
    }
}